A 14-amino acid peptide named for its ability to inhibit pituitary GROWTH HORMONE release, also called somatotropin release-inhibiting factor. It is expressed in the central and peripheral nervous systems, the gut, and other organs. SRIF can also inhibit the release of THYROID-STIMULATING HORMONE; PROLACTIN; INSULIN; and GLUCAGON besides acting as a neurotransmitter and neuromodulator. In a number of species including humans, there is an additional form of somatostatin, SRIF-28 with a 14-amino acid extension at the N-terminal.
Cell surface proteins that bind somatostatin and trigger intracellular changes which influence the behavior of cells. Somatostatin is a hypothalamic hormone, a pancreatic hormone, and a central and peripheral neurotransmitter. Activated somatostatin receptors on pituitary cells inhibit the release of growth hormone; those on endocrine and gastrointestinal cells regulate the absorption and utilization of nutrients; and those on neurons mediate somatostatin's role as a neurotransmitter.
A potent, long-acting synthetic SOMATOSTATIN octapeptide analog that inhibits secretion of GROWTH HORMONE and is used to treat hormone-secreting tumors; DIABETES MELLITUS; HYPOTENSION, ORTHOSTATIC; HYPERINSULINISM; hypergastrinemia; and small bowel fistula.
A 28-amino acid peptide with the same biological activities of somatostatin-14 but with a 14-amino acid extension at the N-terminal. SRIF-28 is the major form of somatostatin in the GASTROINTESTINAL TRACT.
Tumors whose cells possess secretory granules and originate from the neuroectoderm, i.e., the cells of the ectoblast or epiblast that program the neuroendocrine system. Common properties across most neuroendocrine tumors include ectopic hormone production (often via APUD CELLS), the presence of tumor-associated antigens, and isozyme composition.
A family of gastrointestinal peptide hormones that excite the secretion of GASTRIC JUICE. They may also occur in the central nervous system where they are presumed to be neurotransmitters.
Endocrine cells found throughout the GASTROINTESTINAL TRACT and in islets of the PANCREAS. D cells secrete SOMATOSTATIN that acts in both an endocrine and paracrine manner. Somatostatin acts on a variety of tissues including the PITUITARY GLAND; gastrointestinal tract; pancreas; and KIDNEY by inhibiting the release of hormones, such as GROWTH HORMONE; GASTRIN; INSULIN; and RENIN.
A condition caused by prolonged exposure to excessive HUMAN GROWTH HORMONE in adults. It is characterized by bony enlargement of the FACE; lower jaw (PROGNATHISM); hands; FEET; HEAD; and THORAX. The most common etiology is a GROWTH HORMONE-SECRETING PITUITARY ADENOMA. (From Joynt, Clinical Neurology, 1992, Ch36, pp79-80)
A 29-amino acid pancreatic peptide derived from proglucagon which is also the precursor of intestinal GLUCAGON-LIKE PEPTIDES. Glucagon is secreted by PANCREATIC ALPHA CELLS and plays an important role in regulation of BLOOD GLUCOSE concentration, ketone metabolism, and several other biochemical and physiological processes. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1511)
Unstable isotopes of indium that decay or disintegrate emitting radiation. In atoms with atomic weights 106-112, 113m, 114, and 116-124 are radioactive indium isotopes.
Peptides whose amino and carboxy ends are linked together with a peptide bond forming a circular chain. Some of them are ANTI-INFECTIVE AGENTS. Some of them are biosynthesized non-ribosomally (PEPTIDE BIOSYNTHESIS, NON-RIBOSOMAL).
A peptide of 44 amino acids in most species that stimulates the release and synthesis of GROWTH HORMONE. GHRF (or GRF) is synthesized by neurons in the ARCUATE NUCLEUS of the HYPOTHALAMUS. After being released into the pituitary portal circulation, GHRF stimulates GH release by the SOMATOTROPHS in the PITUITARY GLAND.
A usually small, slow-growing neoplasm composed of islands of rounded, oxyphilic, or spindle-shaped cells of medium size, with moderately small vesicular nuclei, and covered by intact mucosa with a yellow cut surface. The tumor can occur anywhere in the gastrointestinal tract (and in the lungs and other sites); approximately 90% arise in the appendix. It is now established that these tumors are of neuroendocrine origin and derive from a primitive stem cell. (From Stedman, 25th ed & Holland et al., Cancer Medicine, 3d ed, p1182)
An iron chelating agent with properties like EDETIC ACID. DTPA has also been used as a chelator for other metals, such as plutonium.
Neoplasms which arise from or metastasize to the PITUITARY GLAND. The majority of pituitary neoplasms are adenomas, which are divided into non-secreting and secreting forms. Hormone producing forms are further classified by the type of hormone they secrete. Pituitary adenomas may also be characterized by their staining properties (see ADENOMA, BASOPHIL; ADENOMA, ACIDOPHIL; and ADENOMA, CHROMOPHOBE). Pituitary tumors may compress adjacent structures, including the HYPOTHALAMUS, several CRANIAL NERVES, and the OPTIC CHIASM. Chiasmal compression may result in bitemporal HEMIANOPSIA.
Cell surface receptors that bind signalling molecules released by neurons and convert these signals into intracellular changes influencing the behavior of cells. Neurotransmitter is used here in its most general sense, including not only messengers that act to regulate ion channels, but also those which act on second messenger systems and those which may act at a distance from their release sites. Included are receptors for neuromodulators, neuroregulators, neuromediators, and neurohumors, whether or not located at synapses.
A polypeptide that is secreted by the adenohypophysis (PITUITARY GLAND, ANTERIOR). Growth hormone, also known as somatotropin, stimulates mitosis, cell differentiation and cell growth. Species-specific growth hormones have been synthesized.
Peptide hormones secreted into the blood by cells in the ISLETS OF LANGERHANS of the pancreas. The alpha cells secrete glucagon; the beta cells secrete insulin; the delta cells secrete somatostatin; and the PP cells secrete pancreatic polypeptide.
A pituitary tumor that secretes GROWTH HORMONE. In humans, excess HUMAN GROWTH HORMONE leads to ACROMEGALY.
Chemical substances having a specific regulatory effect on the activity of a certain organ or organs. The term was originally applied to substances secreted by various ENDOCRINE GLANDS and transported in the bloodstream to the target organs. It is sometimes extended to include those substances that are not produced by the endocrine glands but that have similar effects.
A nodular organ in the ABDOMEN that contains a mixture of ENDOCRINE GLANDS and EXOCRINE GLANDS. The small endocrine portion consists of the ISLETS OF LANGERHANS secreting a number of hormones into the blood stream. The large exocrine portion (EXOCRINE PANCREAS) is a compound acinar gland that secretes several digestive enzymes into the pancreatic ductal system that empties into the DUODENUM.
A 36-amino acid pancreatic hormone that is secreted mainly by endocrine cells found at the periphery of the ISLETS OF LANGERHANS and adjacent to cells containing SOMATOSTATIN and GLUCAGON. Pancreatic polypeptide (PP), when administered peripherally, can suppress gastric secretion, gastric emptying, pancreatic enzyme secretion, and appetite. A lack of pancreatic polypeptide (PP) has been associated with OBESITY in rats and mice.
Tumors or cancer of the ENDOCRINE GLANDS.
Chemical substances which inhibit the function of the endocrine glands, the biosynthesis of their secreted hormones, or the action of hormones upon their specific sites.
Irregular microscopic structures consisting of cords of endocrine cells that are scattered throughout the PANCREAS among the exocrine acini. Each islet is surrounded by connective tissue fibers and penetrated by a network of capillaries. There are four major cell types. The most abundant beta cells (50-80%) secrete INSULIN. Alpha cells (5-20%) secrete GLUCAGON. PP cells (10-35%) secrete PANCREATIC POLYPEPTIDE. Delta cells (~5%) secrete SOMATOSTATIN.
A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1).
A SOMATOSTATIN-secreting tumor derived from the pancreatic delta cells (SOMATOSTATIN-SECRETING CELLS). It is also found in the INTESTINE. Somatostatinomas are associated with DIABETES MELLITUS; CHOLELITHIASIS; STEATORRHEA; and HYPOCHLORHYDRIA. The majority of somatostatinomas have the potential for METASTASIS.
A highly basic, 28 amino acid neuropeptide released from intestinal mucosa. It has a wide range of biological actions affecting the cardiovascular, gastrointestinal, and respiratory systems and is neuroprotective. It binds special receptors (RECEPTORS, VASOACTIVE INTESTINAL PEPTIDE).
Hydrochloric acid present in GASTRIC JUICE.
Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).
A 191-amino acid polypeptide hormone secreted by the human adenohypophysis (PITUITARY GLAND, ANTERIOR), also known as GH or somatotropin. Synthetic growth hormone, termed somatropin, has replaced the natural form in therapeutic usage such as treatment of dwarfism in children with growth hormone deficiency.
A peptide of about 22-amino acids isolated from the DUODENUM. At low pH it inhibits gastric motor activity, whereas at high pH it has a stimulating effect.
A benign tumor of the pancreatic ISLET CELLS. Usually it involves the INSULIN-producing PANCREATIC BETA CELLS, as in INSULINOMA, resulting in HYPERINSULINISM.
A small, unpaired gland situated in the SELLA TURCICA. It is connected to the HYPOTHALAMUS by a short stalk which is called the INFUNDIBULUM.
The region between the sharp indentation at the lower third of the STOMACH (incisura angularis) and the junction of the PYLORUS with the DUODENUM. Pyloric antral glands contain mucus-secreting cells and gastrin-secreting endocrine cells (G CELLS).
Lining of the STOMACH, consisting of an inner EPITHELIUM, a middle LAMINA PROPRIA, and an outer MUSCULARIS MUCOSAE. The surface cells produce MUCUS that protects the stomach from attack by digestive acid and enzymes. When the epithelium invaginates into the LAMINA PROPRIA at various region of the stomach (CARDIA; GASTRIC FUNDUS; and PYLORUS), different tubular gastric glands are formed. These glands consist of cells that secrete mucus, enzymes, HYDROCHLORIC ACID, or hormones.
HORMONES secreted by the gastrointestinal mucosa that affect the timing or the quality of secretion of digestive enzymes, and regulate the motor activity of the digestive system organs.
Compounds that are used in medicine as sources of radiation for radiotherapy and for diagnostic purposes. They have numerous uses in research and industry. (Martindale, The Extra Pharmacopoeia, 30th ed, p1161)
A synthetic pentapeptide that has effects like gastrin when given parenterally. It stimulates the secretion of gastric acid, pepsin, and intrinsic factor, and has been used as a diagnostic aid.
A peptide hormone of about 27 amino acids from the duodenal mucosa that activates pancreatic secretion and lowers the blood sugar level. (USAN and the USP Dictionary of Drug Names, 1994, p597)
Antineoplastic agents that are used to treat hormone-sensitive tumors. Hormone-sensitive tumors may be hormone-dependent, hormone-responsive, or both. A hormone-dependent tumor regresses on removal of the hormonal stimulus, by surgery or pharmacological block. Hormone-responsive tumors may regress when pharmacologic amounts of hormones are administered regardless of whether previous signs of hormone sensitivity were observed. The major hormone-responsive cancers include carcinomas of the breast, prostate, and endometrium; lymphomas; and certain leukemias. (From AMA Drug Evaluations Annual 1994, p2079)
A set of BACTERIAL ADHESINS and TOXINS, BIOLOGICAL produced by BORDETELLA organisms that determine the pathogenesis of BORDETELLA INFECTIONS, such as WHOOPING COUGH. They include filamentous hemagglutinin; FIMBRIAE PROTEINS; pertactin; PERTUSSIS TOXIN; ADENYLATE CYCLASE TOXIN; dermonecrotic toxin; tracheal cytotoxin; Bordetella LIPOPOLYSACCHARIDES; and tracheal colonization factor.
One of the virulence factors produced by BORDETELLA PERTUSSIS. It is a multimeric protein composed of five subunits S1 - S5. S1 contains mono ADPribose transferase activity.
A tetradecapeptide originally obtained from the skins of toads Bombina bombina and B. variegata. It is also an endogenous neurotransmitter in many animals including mammals. Bombesin affects vascular and other smooth muscle, gastric secretion, and renal circulation and function.
A symptom complex associated with CARCINOID TUMOR and characterized by attacks of severe flushing of the skin, diarrheal watery stools, bronchoconstriction, sudden drops in blood pressure, edema, and ascites. The carcinoid tumors are usually located in the gastrointestinal tract and metastasize to the liver. Symptoms are caused by tumor secretion of serotonin, prostaglandins, and other biologically active substances. Cardiac manifestations constitute CARCINOID HEART DISEASE. (Dorland, 27th ed; Stedman, 25th ed)
The amount of a substance secreted by cells or by a specific organ or organism over a given period of time; usually applies to those substances which are formed by glandular tissues and are released by them into biological fluids, e.g., secretory rate of corticosteroids by the adrenal cortex, secretory rate of gastric acid by the gastric mucosa.
A peptide, of about 33 amino acids, secreted by the upper INTESTINAL MUCOSA and also found in the central nervous system. It causes gallbladder contraction, release of pancreatic exocrine (or digestive) enzymes, and affects other gastrointestinal functions. Cholecystokinin may be the mediator of satiety.
Peptides released by NEURONS as intercellular messengers. Many neuropeptides are also hormones released by non-neuronal cells.
Tumors or cancer of the GASTROINTESTINAL TRACT, from the MOUTH to the ANAL CANAL.
A neuropeptide of 29-30 amino acids depending on the species. Galanin is widely distributed throughout the BRAIN; SPINAL CORD; and INTESTINES. There are various subtypes of GALANIN RECEPTORS implicating roles of galanin in regulating FOOD INTAKE; pain perception; memory; and other neuroendocrine functions.
A mercaptoethylamine compound that is endogenously derived from the COENZYME A degradative pathway. The fact that cysteamine is readily transported into LYSOSOMES where it reacts with CYSTINE to form cysteine-cysteamine disulfide and CYSTEINE has led to its use in CYSTINE DEPLETING AGENTS for the treatment of CYSTINOSIS.
A benign tumor of the PANCREATIC BETA CELLS. Insulinoma secretes excess INSULIN resulting in HYPOGLYCEMIA.
RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm.

Somatostatin receptor subtype-5 mediates inhibition of peptide YY secretion from rat intestinal cultures. (1/52)

Somatostatin-14 (S-14) and somatostatin-28 (S-28) bind to five distinct membrane receptors (SSTRs), but S-28 has higher affinity for SSTR-5. Whether S-28 acting through SSTR-5 regulates inhibition of peptide YY (PYY) secretion was tested in fetal rat intestinal cell cultures. S-28 and S-14 caused dose-dependent inhibition of PYY secretion stimulated by gastrin-releasing peptide, but S-28 was more potent than S-14 (EC(50) 0.04 vs. 13.2 nM). PYY was inhibited by two analogs with affinity for SSTR-5, BIM-23268 and BIM-23052, more potently than S-14 and as effectively as S-28. The SSTR-5 analog L-362855 suppressed PYY equivalent only to S-14, but the structurally related peptide L-372588 (Phe to Tyr at position 2) was equipotent to S-28, whereas L-372587 (Phe to Tyr at position 7) caused no inhibition. An SSTR-2 analog decreased PYY secretion similar to S-14, and an SSTR-3 analog was ineffective. PYY secretion stimulated by phorbol 12-myristate 13-acetate and by forskolin was also more potently suppressed by S-28 and the octapeptide SSTR-5 analogs. The results indicate that S-28 mediates inhibition of gastrin-releasing peptide-stimulated PYY secretion through activation of SSTR-5 and includes suppression of cAMP- and protein kinase C-dependent pathways. Substitution of a single hydroxyl group confers differences in SSTR-5 agonist properties, suggesting region specificity for the intrinsic activity of this receptor subtype.  (+info)

Somatostatin-28 regulates GLP-1 secretion via somatostatin receptor subtype 5 in rat intestinal cultures. (2/52)

Five somatostatin receptors (SSTRs) bind somatostatin-14 (S-14) and somatostatin-28 (S-28), but SSTR5 has the highest affinity for S-28. To determine whether S-28 acting through SSTR5 mediates inhibition of glucagon-like peptide-1 (GLP-1), fetal rat intestinal cell cultures were treated with somatostatin analogs with relatively high specificity for SSTRs 2-5. S-28 dose-dependently inhibited GLP-1 secretion stimulated by gastrin-releasing peptide more potently than S-14 (EC(50) 0.01 vs. 5.8 nM). GLP-1 secretion was inhibited by an SSTR5 analog, BIM-23268, more potently than S-14 and nearly as effectively as S-28. The SSTR5 analog L-372,588 also suppressed GLP-1 secretion equivalent to S-28, but a structurally similar peptide, L-362,855 (Tyr to Phe at position 7), was ineffective. An SSTR2-selective analog was less effective than S-28, and an SSTR3 analog was inactive. Separate treatment with GLP-1-(7-36)-NH(2) increased S-28 and S-14 secretion by three- and fivefold; BIM-23268 abolished S-28 without altering S-14, whereas the SSTR2 analog was inactive. The results indicate that somatostatin regulation of GLP-1 secretion occurs via S-28 through activation of SSTR5. GLP-1-stimulated S-28 secretion is also autoregulated by SSTR5 activation, suggesting a feedback loop between GLP-1 and S-28 modulated by SSTR5.  (+info)

A reappraisal of the blood glucose homeostat which comprehensively explains the type 2 diabetes mellitus-syndrome X complex. (3/52)

Blood glucose concentrations are unaffected by exercise despite very high rates of glucose flux. The plasma ionised calcium levels are even more tightly controlled after meals and during lactation. This implies 'integral control'. However, pairs of integral counterregulatory controllers (e.g. insulin and glucagon, or calcitonin and parathyroid hormone) cannot operate on the same controlled variable, unless there is some form of mutual inhibition. Flip-flop functional coupling between pancreatic alpha- and beta-cells via gap junctions may provide such a mechanism. Secretion of a common inhibitory chromogranin by the parathyroids and the thyroidal C-cells provides another. Here we describe how the insulin:glucagon flip-flop controller can be complemented by growth hormone, despite both being integral controllers. Homeostatic conflict is prevented by somatostatin-28 secretion from both the hypothalamus and the pancreatic islets. Our synthesis of the information pertaining to the glucose homeostat that has accumulated in the literature predicts that disruption of the flip-flop mechanism by the accumulation of amyloid in the pancreatic islets in type 2 diabetes mellitus will lead to hyperglucagonaemia, hyperinsulinaemia, insulin resistance, glucose intolerance and impaired insulin responsiveness to elevated blood glucose levels. It explains syndrome X (or metabolic syndrome) as incipient type 2 diabetes in which the glucose control system, while impaired, can still maintain blood glucose at the desired level. It also explains why it is characterised by high plasma insulin levels and low plasma growth hormone levels, despite normoglycaemia, and how this leads to central obesity, dyslipidaemia and cardiovascular disease in both syndrome X and type 2 diabetes.  (+info)

Somatostatin-14 neurons in the ovine hypothalamus: colocalization with estrogen receptor alpha and somatostatin-28(1-12) immunoreactivity, and activation in response to estradiol. (4/52)

Pituitary gland growth hormone (GH) secretion is influenced by two hypothalamic neuropeptides: growth hormone-releasing hormone (GHRH) and somatostatin. Recent data also suggest that estrogen modulates GH release, particularly at the time of the preovulatory luteinizing hormone surge, when a coincident surge of GH is observed in sheep. The GHRH neurons do not possess estrogen receptor alpha (ERalpha), suggesting that estrogen does not act directly on GHRH neurons. Similarly, few somatotropes express ERalpha, suggesting a weak pituitary effect of estradiol on GH. It was hypothesized, therefore, that estradiol may affect somatostatin neurons to modulate GH release from the pituitary. Using immunocytochemical approaches, the present study revealed that although somatostatin neurons were located in several hypothalamic sites, only those in the arcuate nucleus (13% +/- 2%) and ventromedial nucleus (VMN; 29% +/- 1%) expressed ERalpha. In addition, we found that all neurons immunoreactive for somatostatin-14 were also immunoreactive for somatostatin-28(1-12). To determine whether increased GH secretion in response to estradiol is through modulation of GHRH and/or somatostatin neuronal activity, a final study investigated whether c-fos expression increased in somatostatin- and GHRH-immunoreactive cells at the time of the estradiol-induced LH surge in intact anestrous ewes. Estradiol significantly (P < 0.05) increased the percentage of GHRH (estradiol, 75% +/- 3%; no estradiol, 19% +/- 2%) neurons expressing c-fos in the hypothalamus. The percentage of somatostatin-immunoreactive neurons coexpressing c-fos in the estradiol-treated animals was significantly (P < 0.05) higher (periventricular, 44% +/- 3%; arcuate, 72% +/- 5%; VMN, 81% +/- 5%) than in the control animals (periventricular, 22% +/- 1%; arcuate, 29% +/- 3%; VMN, 31% +/- 3%). The present study suggests that estradiol modulates the activity of GHRH and somatostatin neurons but that this effect is most likely mediated through an indirect interneuronal pathway.  (+info)

Molecular cloning of a somatostatin-28 receptor and comparison of its expression pattern with that of a somatostatin-14 receptor in rat brain. (5/52)

The tetradecapeptide somatotropin-release inhibiting factor somatostatin-14 regulates the release of peptide hormones and also functions as neurotransmitter. The octacosapeptide somatostatin-28, the N-terminally extended form of somatostatin-14, shows similar biological activities yet with different potencies. Both peptides most likely function through distinct receptors. Here we report on the molecular and functional characterization of a somatostatin-28 receptor (SSR-28) cloned from a rat brain cDNA library. The nucleotide sequence contains an open reading frame for a protein of 428 amino acid residues with a predicted molecular mass of 47 kDa. Binding assays using radiolabeled somatostatin-14 and membranes from COS cells transfected with the cloned cDNA show that this receptor, SSR-28, has a higher binding affinity for somatostatin-28 (IC50 = 0.24 nM) than for somatostatin-14 (IC50 = 0.89 nM). RNA blot analysis reveals a 4.4-kilobase mRNA in rat cerebellum and at significantly lower abundance in other brain regions. In situ hybridization indicates that SSR-28 mRNA is present in the granular and Purkinje cell layers of the cerebellum and in the large cells of the hypoglossal nucleus of the brain stem. Signals for SSR-28 mRNA do not overlap with those of a previously cloned rat receptor that preferentially binds somatostatin-14 (SSR-14). SSR-14 mRNA is found in the medial cerebellar nucleus, horizontal limb of the diagonal band, various hypothalamic nuclei, and in layers IV and V of the cortex. In the rat cerebellum, SSR-14 and SSR-28 mRNAs are developmentally regulated; the levels of the former are highest around birth and levels of the latter are highest at the adult stage.  (+info)

Solubilization and partial purification of somatostatin-28 preferring receptors from hamster pancreatic beta cells. (6/52)

Somatostatin-28 (SRIF-28) preferring receptors were solubilized from hamster beta cell insulinoma using the zwitterionic detergent 3-[(3-cholamidopropyl) dimethylammonio]-1-propanesulfonate. The binding of the iodinated [Leu8-D-TRP22-Tyr25]SRIF-28 analog (referred to as 125I[LWY] SRIF-28) to the solubilized fraction was time-dependent, saturable, and reversible. Scatchard analysis of equilibrium binding data indicated that the solubilized extract contained two classes of SRIF-28-binding sites: a high affinity site (Kd = 0.3 nM and Bmax = 1 pmol/mg protein) and a low affinity site (Kd = 13 nM and Bmax = 4.7 pmol/mg protein). The binding of 125I[LWY]SRIF-28 to solubilized SRIF-28 receptors was sensitive to the GTP analog guanosine-5'-O-thiotriphosphate, suggesting that receptors are functionally linked to a G-protein. By anion-exchange chromatography of the solubilized extract followed by chromatography on wheat germ agglutinin, a 46-fold purification of SRIF-28 receptors was obtained. At this stage of purification, only high affinity sites were found (Kd = 1 nM) and the GTP effect was not maintained. A specific protein of 37 kDa was identified by sodium dodecyl sulfate-polyacrylamide gel electrophoresis after photoaffinity labeling. We suggest that this protein is the putative SRIF-28 receptor or a subunit thereof.  (+info)

Identification of oligopeptidase B in higher plants. Purification and characterization of oligopeptidase B from quiescent wheat embryo, Triticum aestivum. (7/52)

Proteolytic enzymes in general, and cysteine proteases in particular, play key roles in seed germination and early seedling growth. However, the precise mechanism by which the serine proteases are regulated remains unclear. Trypsin-like activity was detected in wheat germ (quiescent embryo) and this activity increased in the germinating embryo. In this work, a trypsin-like serine protease expressed in wheat germ was purified to homogeneity by chromatography through DEAE-cellulose, phenyl-Sepharose, Ultrogel AcA-34 and Blue-Sepharose. The molecular mass of the enzyme was estimated to be 81 kDa by SDS-PAGE under reducing conditions. Amino acid analysis of the peptides generated following digestion of the enzyme with lysyl endopeptidase indicated that the enzyme is a plant homologue of Escherichia. coli oligopeptidase B. The subsite specificity of the enzymes differ, although both enzymes hydrolyze synthetic substrates and model peptides at the carboxyl side of basic amino acids. The wheat enzyme is more sensitive to leupeptin and antipain than the E. coli emzyme. These results provide the basis for characterizing plant oligopeptidase B and contribute to our understanding of its role in the early development of seedlings.  (+info)

Differential efficacies of somatostatin receptor agonists for G-protein activation and desensitization of somatostatin receptor subtype 4-mediated responses. (8/52)

Although desensitization represents an important physiological feedback mechanism that protects against overstimulation, it can significantly limit the therapeutic usefulness of drugs. In the current investigation, we have employed Cytosensor microphysiometry for the purpose of determining the propensity of somatostatin receptor agonists to induce desensitization of the human somatostatin receptor subtype 4 (h sst4)-mediated extracellular acidification rate (EAR) response in intact Chinese hamster ovary (CHO) cells. We have compared this propensity with the efficacies of the agonists as measured in a [35S]guanosine-5'-O-(3-thio)triphosphate binding assay with membranes of the same CHO-h sst4 cell line. We observed that (1'S,2S)-4-amino-N-(1'-carbamoyl-2'-phenylethyl)-2-(4''-methyl-1''-naphthalenesul fonylamino)butanamide (J-2156), a superagonist at the h sst4 with higher efficacy than somatostatin-14 itself (Engstrom et al., 2005), was considerably less prone to cause desensitization of the EAR response than somatostatin-14, somatostatin-28, and cortistatin-17. In contrast, compound A (methyl (2S)-5-{[amino(imino)methyl]amino}-2-{[4-[5-7-difluoro-2-phenyl-1H-indol-3-yl)but anoyl]amino}-pentanoate), which we also found to be an h sst(4) superagonist, albeit to a lesser degree than J-2156, demonstrated a high propensity to cause desensitization. Our results indicate that there is no relationship between the efficacy of the agonists to cause G-protein activation and their ability to induce desensitization of the h sst4-mediated EAR responses. The finding that on the h sst4, J-2156 is not only a superagonist but also shows a low propensity to cause desensitization, might offer therapeutic advantages. At a minimum, the compound will be a powerful tool to study the mechanisms connected to efficacy and desensitization of h sst4-mediated responses.  (+info)

Somatostatin is a hormone that inhibits the release of several hormones and also has a role in slowing down digestion. It is produced by the body in various parts of the body, including the hypothalamus (a part of the brain), the pancreas, and the gastrointestinal tract.

Somatostatin exists in two forms: somatostatin-14 and somatostatin-28, which differ in their length. Somatostatin-14 is the predominant form found in the brain, while somatostatin-28 is the major form found in the gastrointestinal tract.

Somatostatin has a wide range of effects on various physiological processes, including:

* Inhibiting the release of several hormones such as growth hormone, insulin, glucagon, and gastrin
* Slowing down digestion by inhibiting the release of digestive enzymes from the pancreas and reducing blood flow to the gastrointestinal tract
* Regulating neurotransmission in the brain

Somatostatin is used clinically as a diagnostic tool for detecting certain types of tumors that overproduce growth hormone or other hormones, and it is also used as a treatment for some conditions such as acromegaly (a condition characterized by excessive growth hormone production) and gastrointestinal disorders.

Somatostatin receptors (SSTRs) are a group of G protein-coupled receptors that bind to the neuropeptide hormone somatostatin. There are five subtypes of SSTRs, named SSTR1 through SSTR5, each with distinct physiological roles and tissue distributions.

Somatostatin is a small peptide that is widely distributed throughout the body, including in the central nervous system, gastrointestinal tract, pancreas, and other endocrine organs. It has multiple functions, including inhibition of hormone release, regulation of cell proliferation, and modulation of neurotransmission.

SSTRs are expressed on the surface of many different types of cells, including neurons, endocrine cells, and immune cells. They play important roles in regulating various physiological processes, such as inhibiting the release of hormones like insulin, glucagon, and growth hormone. SSTRs have also been implicated in a number of pathophysiological conditions, including cancer, neurodegenerative diseases, and inflammatory disorders.

In recent years, SSTRs have become an important target for the development of new therapeutic strategies, particularly in the treatment of neuroendocrine tumors (NETs). Several radiolabeled somatostatin analogues have been developed that can selectively bind to SSTRs on NET cells and deliver targeted radiation therapy. These agents have shown promising results in clinical trials and are now being used as standard of care for patients with advanced NETs.

Octreotide is a synthetic analogue of the natural hormone somatostatin, which is used in medical treatment. It is a octapeptide with similar effects to somatostatin, but with a longer duration of action. Octreotide is primarily used in the management of acromegaly, gastroenteropancreatic neuroendocrine tumors (GEP-NETs), and diarrhea and flushing associated with carcinoid syndrome.

It works by inhibiting the release of several hormones, including growth hormone, insulin, glucagon, and gastrin. This results in a decrease in symptoms caused by excessive hormone secretion, such as reduced growth hormone levels in acromegaly, decreased tumor size in some GEP-NETs, and improved diarrhea and flushing in carcinoid syndrome.

Octreotide is available in several forms, including short-acting subcutaneous injections (Sandostatin®), long-acting depot intramuscular injections (Sandostatin LAR®), and a slow-release formulation for the treatment of diarrhea associated with AIDS (Mycapssa™).

The medical definition of Octreotide is:

A synthetic octapeptide analogue of somatostatin, used in the management of acromegaly, gastroenteropancreatic neuroendocrine tumors (GEP-NETs), and diarrhea and flushing associated with carcinoid syndrome. Octreotide inhibits the release of several hormones, including growth hormone, insulin, glucagon, and gastrin, leading to symptomatic improvement in these conditions. It is available as short-acting subcutaneous injections, long-acting depot intramuscular injections, and a slow-release formulation for diarrhea associated with AIDS.

Somatostatin-28 is a form of somatostatin, which is a naturally occurring hormone in the body that inhibits the release of several hormones and also acts as a neurotransmitter. Somatostatin exists in two major forms, namely somatostatin-14 and somatostatin-28, with the latter being a longer variant containing 28 amino acids.

Somatostatin-28 is produced by various tissues, including the hypothalamus, pancreas, and gastrointestinal tract. It exerts its effects through specific receptors (SST1-5) that are widely distributed in the body. Somatostatin-28 has a higher potency than somatostatin-14 in inhibiting the release of several hormones such as growth hormone, thyroid-stimulating hormone, insulin, glucagon, and gastrin.

In addition to its endocrine functions, somatostatin-28 also has neuromodulatory effects on the central nervous system, where it regulates neurotransmission and neural excitability. Overall, somatostatin-28 plays a crucial role in regulating various physiological processes, including hormonal homeostasis, appetite regulation, and neurotransmission.

Neuroendocrine tumors (NETs) are a diverse group of neoplasms that arise from cells of the neuroendocrine system, which is composed of dispersed neuroendocrine cells throughout the body, often in close association with nerves and blood vessels. These cells have the ability to produce and secrete hormones or hormone-like substances in response to various stimuli. NETs can occur in a variety of organs, including the lungs, pancreas, small intestine, colon, rectum, stomach, and thyroid gland, as well as in some less common sites such as the thymus, adrenal glands, and nervous system.

NETs can be functional or nonfunctional, depending on whether they produce and secrete hormones or hormone-like substances that cause specific symptoms related to hormonal excess. Functional NETs may give rise to a variety of clinical syndromes, such as carcinoid syndrome, Zollinger-Ellison syndrome, pancreatic neuroendocrine tumor syndrome (also known as Verner-Morrison or WDHA syndrome), and others. Nonfunctional NETs are more likely to present with symptoms related to the size and location of the tumor, such as abdominal pain, intestinal obstruction, or bleeding.

The diagnosis of NETs typically involves a combination of imaging studies, biochemical tests (e.g., measurement of serum hormone levels), and histopathological examination of tissue samples obtained through biopsy or surgical resection. Treatment options depend on the type, location, stage, and grade of the tumor, as well as the presence or absence of functional symptoms. They may include surgery, radiation therapy, chemotherapy, targeted therapy, and/or peptide receptor radionuclide therapy (PRRT).

Gastrins are a group of hormones that are produced by G cells in the stomach lining. These hormones play an essential role in regulating gastric acid secretion and motor functions of the gastrointestinal tract. The most well-known gastrin is known as "gastrin-17," which is released into the bloodstream and stimulates the release of hydrochloric acid from parietal cells in the stomach lining.

Gastrins are stored in secretory granules within G cells, and their release is triggered by several factors, including the presence of food in the stomach, gastrin-releasing peptide (GRP), and vagus nerve stimulation. Once released, gastrins bind to specific receptors on parietal cells, leading to an increase in intracellular calcium levels and the activation of enzymes that promote hydrochloric acid secretion.

Abnormalities in gastrin production can lead to several gastrointestinal disorders, including gastrinomas (tumors that produce excessive amounts of gastrin), which can cause severe gastric acid hypersecretion and ulcers. Conversely, a deficiency in gastrin production can result in hypochlorhydria (low stomach acid levels) and impaired digestion.

Somatostatin-secreting cells, also known as delta cells or D cells, are a type of neuroendocrine cell found in the pancreatic islets and the central nervous system. These cells produce and secrete somatostatin, a peptide hormone that inhibits the release of several other hormones such as insulin, glucagon, and gastrin.

Somatostatin has a wide range of physiological effects, including inhibition of gastrointestinal motility, secretion, and blood flow; modulation of neurotransmission; and regulation of cell growth and differentiation. Somatostatin-secreting cells play an essential role in maintaining hormonal homeostasis by regulating the release of other hormones in response to various physiological stimuli.

In the pancreas, somatostatin-secreting cells are located in the islets of Langerhans, where they represent about 10% of the endocrine cell population. They are scattered among the insulin-producing beta cells and glucagon-producing alpha cells and form a dense network of fine processes that surround other islet cells. Somatostatin released from these cells acts in a paracrine manner to regulate the secretion of insulin, glucagon, and other hormones produced by the islet cells.

In the central nervous system, somatostatin-secreting cells are found in various regions, including the hypothalamus, hippocampus, and cortex. They play a role in regulating neurotransmission, neuronal excitability, and synaptic plasticity. Dysfunction of somatostatin-secreting cells has been implicated in several neurological and endocrine disorders, such as diabetes, acromegaly, and certain types of tumors.

Acromegaly is a rare hormonal disorder that typically occurs in middle-aged adults. It results from the pituitary gland producing too much growth hormone (GH) during adulthood. The excessive production of GH leads to abnormal growth of body tissues, particularly in the hands, feet, and face.

The term "acromegaly" is derived from two Greek words: "akros," meaning extremities, and "megaly," meaning enlargement. In most cases, acromegaly is caused by a benign tumor (adenoma) of the pituitary gland, which results in overproduction of GH.

Common symptoms include enlarged hands and feet, coarse facial features, deepened voice, joint pain, and sweating. If left untreated, acromegaly can lead to serious complications such as diabetes, hypertension, heart disease, and arthritis. Treatment usually involves surgical removal of the tumor, radiation therapy, or medication to control GH production.

Glucagon is a hormone produced by the alpha cells of the pancreas. Its main function is to regulate glucose levels in the blood by stimulating the liver to convert stored glycogen into glucose, which can then be released into the bloodstream. This process helps to raise blood sugar levels when they are too low, such as during hypoglycemia.

Glucagon is a 29-amino acid polypeptide that is derived from the preproglucagon protein. It works by binding to glucagon receptors on liver cells, which triggers a series of intracellular signaling events that lead to the activation of enzymes involved in glycogen breakdown.

In addition to its role in glucose regulation, glucagon has also been shown to have other physiological effects, such as promoting lipolysis (the breakdown of fat) and inhibiting gastric acid secretion. Glucagon is often used clinically in the treatment of hypoglycemia, as well as in diagnostic tests to assess pancreatic function.

Indium radioisotopes refer to specific types of radioactive indium atoms, which are unstable and emit radiation as they decay. Indium is a chemical element with the symbol In and atomic number 49. Its radioisotopes are often used in medical imaging and therapy due to their unique properties.

For instance, one commonly used indium radioisotope is Indium-111 (^111In), which has a half-life of approximately 2.8 days. It emits gamma rays, making it useful for diagnostic imaging techniques such as single-photon emission computed tomography (SPECT). In clinical applications, indium-111 is often attached to specific molecules or antibodies that target particular cells or tissues in the body, allowing medical professionals to monitor biological processes and identify diseases like cancer.

Another example is Indium-113m (^113mIn), which has a half-life of about 99 minutes. It emits low-energy gamma rays and is used as a source for in vivo counting, typically in the form of indium chloride (InCl3) solution. This radioisotope can be used to measure blood flow, ventilation, and other physiological parameters.

It's important to note that handling and using radioisotopes require proper training and safety measures due to their ionizing radiation properties.

Cyclic peptides are a type of peptides in which the N-terminus and C-terminus of the peptide chain are linked to form a circular structure. This is in contrast to linear peptides, which have a straight peptide backbone with a free N-terminus and C-terminus. The cyclization of peptides can occur through various mechanisms, including the formation of an amide bond between the N-terminal amino group and the C-terminal carboxylic acid group (head-to-tail cyclization), or through the formation of a bond between side chain functional groups.

Cyclic peptides have unique structural and chemical properties that make them valuable in medical and therapeutic applications. For example, they are more resistant to degradation by enzymes compared to linear peptides, which can increase their stability and half-life in the body. Additionally, the cyclic structure allows for greater conformational rigidity, which can enhance their binding affinity and specificity to target molecules.

Cyclic peptides have been explored as potential therapeutics for a variety of diseases, including cancer, infectious diseases, and neurological disorders. They have also been used as tools in basic research to study protein-protein interactions and cell signaling pathways.

Growth Hormone-Releasing Hormone (GHRH) is a hormone that is produced and released by the hypothalamus, a small gland located in the brain. Its primary function is to stimulate the anterior pituitary gland to release growth hormone (GH) into the bloodstream. GH plays a crucial role in growth and development, particularly during childhood and adolescence, by promoting the growth of bones and muscles.

GHRH is a 44-amino acid peptide that binds to specific receptors on the surface of pituitary cells, triggering a series of intracellular signals that ultimately lead to the release of GH. The production and release of GHRH are regulated by various factors, including sleep, stress, exercise, and nutrition.

Abnormalities in the production or function of GHRH can lead to growth disorders, such as dwarfism or gigantism, as well as other hormonal imbalances. Therefore, understanding the role of GHRH in regulating GH release is essential for diagnosing and treating these conditions.

A carcinoid tumor is a type of slow-growing neuroendocrine tumor that usually originates in the digestive tract, particularly in the small intestine. These tumors can also arise in other areas such as the lungs, appendix, and rarely in other organs. Carcinoid tumors develop from cells of the diffuse endocrine system (also known as the neuroendocrine system) that are capable of producing hormones or biologically active amines.

Carcinoid tumors can produce and release various hormones and bioactive substances, such as serotonin, histamine, bradykinins, prostaglandins, and tachykinins, which can lead to a variety of symptoms. The most common syndrome associated with carcinoid tumors is the carcinoid syndrome, characterized by flushing, diarrhea, abdominal cramping, and wheezing or difficulty breathing.

Carcinoid tumors are typically classified as functional or nonfunctional based on whether they produce and secrete hormones that cause symptoms. Functional carcinoid tumors account for approximately 30% of cases and can lead to the development of carcinoid syndrome, while nonfunctional tumors do not produce significant amounts of hormones and are often asymptomatic until they grow large enough to cause local or distant complications.

Treatment options for carcinoid tumors depend on the location, size, and extent of the tumor, as well as whether it is functional or nonfunctional. Treatment may include surgery, medications (such as somatostatin analogs, chemotherapy, or targeted therapies), and radiation therapy. Regular follow-up with imaging studies and biochemical tests is essential to monitor for recurrence and assess treatment response.

Pentetic Acid, also known as DTPA (Diethylenetriaminepentaacetic acid), is not a medication itself but a chelating agent used in the preparation of pharmaceutical products. A chelating agent is a compound that can form multiple bonds with metal ions, allowing them to be excreted from the body.

Pentetic Acid is used in medical treatments to remove or decrease the levels of certain toxic metals, such as lead, plutonium, americium, and curium, from the body. It can be given intravenously or orally, depending on the specific situation and the formulation of the medication.

It is important to note that the use of Pentetic Acid should be under the supervision of a healthcare professional, as it can also bind to essential metals like zinc, calcium, and iron, which can lead to deficiencies if not properly managed.

Pituitary neoplasms refer to abnormal growths or tumors in the pituitary gland, a small endocrine gland located at the base of the brain. These neoplasms can be benign (non-cancerous) or malignant (cancerous), with most being benign. They can vary in size and may cause various symptoms depending on their location, size, and hormonal activity.

Pituitary neoplasms can produce and secrete excess hormones, leading to a variety of endocrine disorders such as Cushing's disease (caused by excessive ACTH production), acromegaly (caused by excessive GH production), or prolactinoma (caused by excessive PRL production). They can also cause local compression symptoms due to their size, leading to headaches, vision problems, and cranial nerve palsies.

The exact causes of pituitary neoplasms are not fully understood, but genetic factors, radiation exposure, and certain inherited conditions may increase the risk of developing these tumors. Treatment options for pituitary neoplasms include surgical removal, radiation therapy, and medical management with drugs that can help control hormonal imbalances.

Neurotransmitter receptors are specialized protein molecules found on the surface of neurons and other cells in the body. They play a crucial role in chemical communication within the nervous system by binding to specific neurotransmitters, which are chemicals that transmit signals across the synapse (the tiny gap between two neurons).

When a neurotransmitter binds to its corresponding receptor, it triggers a series of biochemical events that can either excite or inhibit the activity of the target neuron. This interaction helps regulate various physiological processes, including mood, cognition, movement, and sensation.

Neurotransmitter receptors can be classified into two main categories based on their mechanism of action: ionotropic and metabotropic receptors. Ionotropic receptors are ligand-gated ion channels that directly allow ions to flow through the cell membrane upon neurotransmitter binding, leading to rapid changes in neuronal excitability. In contrast, metabotropic receptors are linked to G proteins and second messenger systems, which modulate various intracellular signaling pathways more slowly.

Examples of neurotransmitters include glutamate, GABA (gamma-aminobutyric acid), dopamine, serotonin, acetylcholine, and norepinephrine, among others. Each neurotransmitter has its specific receptor types, which may have distinct functions and distributions within the nervous system. Understanding the roles of these receptors and their interactions with neurotransmitters is essential for developing therapeutic strategies to treat various neurological and psychiatric disorders.

Growth Hormone (GH), also known as somatotropin, is a peptide hormone secreted by the somatotroph cells in the anterior pituitary gland. It plays a crucial role in regulating growth, cell reproduction, and regeneration by stimulating the production of another hormone called insulin-like growth factor 1 (IGF-1) in the liver and other tissues. GH also has important metabolic functions, such as increasing glucose levels, enhancing protein synthesis, and reducing fat storage. Its secretion is regulated by two hypothalamic hormones: growth hormone-releasing hormone (GHRH), which stimulates its release, and somatostatin (SRIF), which inhibits its release. Abnormal levels of GH can lead to various medical conditions, such as dwarfism or gigantism if there are deficiencies or excesses, respectively.

Pancreatic hormones are chemical messengers produced and released by the pancreas, a gland located in the abdomen. The two main types of pancreatic hormones are insulin and glucagon, which are released by specialized cells called islets of Langerhans.

Insulin is produced by beta cells and helps regulate blood sugar levels by allowing cells in the body to take in sugar (glucose) from the bloodstream. It also helps the body store excess glucose in the liver for later use.

Glucagon is produced by alpha cells and has the opposite effect of insulin. When blood sugar levels are low, glucagon stimulates the release of stored glucose from the liver to raise blood sugar levels.

Together, insulin and glucagon help maintain balanced blood sugar levels and are essential for the proper functioning of the body's metabolism. Other hormones produced by the pancreas include somatostatin, which regulates the release of insulin and glucagon, and gastrin, which stimulates the production of digestive enzymes in the stomach.

A Growth Hormone-Secreting Pituitary Adenoma (GH-secreting pituitary adenoma, or GHoma) is a type of benign tumor that develops in the pituitary gland and results in excessive production of growth hormone (GH). This leads to a condition known as acromegaly if it occurs in adults, or gigantism if it occurs in children before the closure of the growth plates.

Symptoms of GH-secreting pituitary adenoma may include:

1. Coarsening of facial features
2. Enlargement of hands and feet
3. Deepened voice due to thickening of vocal cords
4. Increased sweating and body odor
5. Joint pain and stiffness
6. Sleep apnea
7. Fatigue, weakness, or muscle wasting
8. Headaches
9. Vision problems
10. Irregular menstrual periods in women
11. Erectile dysfunction in men

Diagnosis typically involves measuring the levels of GH and insulin-like growth factor 1 (IGF-1) in the blood, along with imaging tests like MRI or CT scans to locate and characterize the tumor. Treatment options include surgical removal of the tumor, radiation therapy, and medication to control GH production. Regular follow-ups are necessary to monitor for potential recurrence.

Hormones are defined as chemical messengers that are produced by endocrine glands or specialized cells and are transported through the bloodstream to tissues and organs, where they elicit specific responses. They play crucial roles in regulating various physiological processes such as growth, development, metabolism, reproduction, and mood. Examples of hormones include insulin, estrogen, testosterone, adrenaline, and thyroxine.

The pancreas is a glandular organ located in the abdomen, posterior to the stomach. It has both exocrine and endocrine functions. The exocrine portion of the pancreas consists of acinar cells that produce and secrete digestive enzymes into the duodenum via the pancreatic duct. These enzymes help in the breakdown of proteins, carbohydrates, and fats in food.

The endocrine portion of the pancreas consists of clusters of cells called islets of Langerhans, which include alpha, beta, delta, and F cells. These cells produce and secrete hormones directly into the bloodstream, including insulin, glucagon, somatostatin, and pancreatic polypeptide. Insulin and glucagon are critical regulators of blood sugar levels, with insulin promoting glucose uptake and storage in tissues and glucagon stimulating glycogenolysis and gluconeogenesis to raise blood glucose when it is low.

Pancreatic polypeptide (PP) is a hormone that is produced and released by the pancreas, specifically by the F cells located in the islets of Langerhans. It is a small protein consisting of 36 amino acids, and it plays a role in regulating digestive functions, particularly by inhibiting pancreatic enzyme secretion and gastric acid secretion.

PP is released into the bloodstream in response to food intake, especially when nutrients such as proteins and fats are present in the stomach. It acts on the brain to produce a feeling of fullness or satiety, which helps to regulate appetite and eating behavior. Additionally, PP has been shown to have effects on glucose metabolism, insulin secretion, and energy balance.

In recent years, there has been growing interest in the potential therapeutic uses of PP for a variety of conditions, including obesity, diabetes, and gastrointestinal disorders. However, more research is needed to fully understand its mechanisms of action and clinical applications.

Endocrine gland neoplasms refer to abnormal growths (tumors) that develop in the endocrine glands. These glands are responsible for producing hormones, which are chemical messengers that regulate various functions and processes in the body. Neoplasms can be benign or malignant (cancerous). Benign neoplasms tend to grow slowly and do not spread to other parts of the body. Malignant neoplasms, on the other hand, can invade nearby tissues and organs and may also metastasize (spread) to distant sites.

Endocrine gland neoplasms can occur in any of the endocrine glands, including:

1. Pituitary gland: located at the base of the brain, it produces several hormones that regulate growth and development, as well as other bodily functions.
2. Thyroid gland: located in the neck, it produces thyroid hormones that regulate metabolism and calcium balance.
3. Parathyroid glands: located near the thyroid gland, they produce parathyroid hormone that regulates calcium levels in the blood.
4. Adrenal glands: located on top of each kidney, they produce hormones such as adrenaline, cortisol, and aldosterone that regulate stress response, metabolism, and blood pressure.
5. Pancreas: located behind the stomach, it produces insulin and glucagon, which regulate blood sugar levels, and digestive enzymes that help break down food.
6. Pineal gland: located in the brain, it produces melatonin, a hormone that regulates sleep-wake cycles.
7. Gonads (ovaries and testicles): located in the pelvis (ovaries) and scrotum (testicles), they produce sex hormones such as estrogen, progesterone, and testosterone that regulate reproductive function and secondary sexual characteristics.

Endocrine gland neoplasms can cause various symptoms depending on the type and location of the tumor. For example, a pituitary gland neoplasm may cause headaches, vision problems, or hormonal imbalances, while an adrenal gland neoplasm may cause high blood pressure, weight gain, or mood changes.

Diagnosis of endocrine gland neoplasms typically involves a combination of medical history, physical examination, imaging studies such as CT or MRI scans, and laboratory tests to measure hormone levels. Treatment options may include surgery, radiation therapy, chemotherapy, or hormonal therapy, depending on the type and stage of the tumor.

Hormone antagonists are substances or drugs that block the action of hormones by binding to their receptors without activating them, thereby preventing the hormones from exerting their effects. They can be classified into two types: receptor antagonists and enzyme inhibitors. Receptor antagonists bind directly to hormone receptors and prevent the hormone from binding, while enzyme inhibitors block the production or breakdown of hormones by inhibiting specific enzymes involved in their metabolism. Hormone antagonists are used in the treatment of various medical conditions, such as cancer, hormonal disorders, and cardiovascular diseases.

The Islets of Langerhans are clusters of specialized cells within the pancreas, an organ located behind the stomach. These islets are named after Paul Langerhans, who first identified them in 1869. They constitute around 1-2% of the total mass of the pancreas and are distributed throughout its substance.

The Islets of Langerhans contain several types of cells, including:

1. Alpha (α) cells: These produce and release glucagon, a hormone that helps to regulate blood sugar levels by promoting the conversion of glycogen to glucose in the liver when blood sugar levels are low.
2. Beta (β) cells: These produce and release insulin, a hormone that promotes the uptake and utilization of glucose by cells throughout the body, thereby lowering blood sugar levels.
3. Delta (δ) cells: These produce and release somatostatin, a hormone that inhibits the release of both insulin and glucagon and helps regulate their secretion in response to changing blood sugar levels.
4. PP cells (gamma or γ cells): These produce and release pancreatic polypeptide, which plays a role in regulating digestive enzyme secretion and gastrointestinal motility.

Dysfunction of the Islets of Langerhans can lead to various endocrine disorders, such as diabetes mellitus, where insulin-producing beta cells are damaged or destroyed, leading to impaired blood sugar regulation.

Insulin is a hormone produced by the beta cells of the pancreatic islets, primarily in response to elevated levels of glucose in the circulating blood. It plays a crucial role in regulating blood glucose levels and facilitating the uptake and utilization of glucose by peripheral tissues, such as muscle and adipose tissue, for energy production and storage. Insulin also inhibits glucose production in the liver and promotes the storage of excess glucose as glycogen or triglycerides.

Deficiency in insulin secretion or action leads to impaired glucose regulation and can result in conditions such as diabetes mellitus, characterized by chronic hyperglycemia and associated complications. Exogenous insulin is used as a replacement therapy in individuals with diabetes to help manage their blood glucose levels and prevent long-term complications.

Somatostatinoma is a rare type of neuroendocrine tumor that originates from the delta cells (D cells) of the diffuse endocrine system, which are responsible for producing and secreting somatostatin, a hormone that inhibits the release of several other hormones. These tumors can occur in various organs, but they most commonly arise in the pancreas and the small intestine (duodenum).

Somatostatinomas are typically slow-growing and can be functional or nonfunctional. Functional somatostatinomas actively produce and secrete excessive amounts of somatostatin, which can lead to a variety of clinical symptoms due to the inhibition of other hormones' functions. Nonfunctional somatostatinomas do not secrete significant amounts of somatostatin and are often discovered incidentally during imaging studies or when they cause local mass effects.

Common symptoms associated with functional somatostatinomas include diarrhea, abdominal pain, weight loss, fat malabsorption, and steatorrhea (fatty stools). They can also lead to diabetes mellitus due to the inhibition of insulin secretion. Additionally, these tumors may cause symptoms related to hormone deficiencies or the compression of nearby structures, depending on their location.

Diagnosis typically involves imaging studies such as CT scans, MRI, and PET scans, along with biochemical tests to measure somatostatin levels in the blood. A definitive diagnosis usually requires a tissue biopsy or surgical removal of the tumor for histopathological examination. Treatment options include surgery, chemotherapy, radiation therapy, and targeted therapies, depending on the stage and location of the tumor.

Vasoactive Intestinal Peptide (VIP) is a 28-amino acid polypeptide hormone that has potent vasodilatory, secretory, and neurotransmitter effects. It is widely distributed throughout the body, including in the gastrointestinal tract, where it is synthesized and released by nerve cells (neurons) in the intestinal mucosa. VIP plays a crucial role in regulating various physiological functions such as intestinal secretion, motility, and blood flow. It also has immunomodulatory effects and may play a role in neuroprotection. High levels of VIP are found in the brain, where it acts as a neurotransmitter or neuromodulator and is involved in various cognitive functions such as learning, memory, and social behavior.

Gastric acid, also known as stomach acid, is a digestive fluid produced in the stomach. It's primarily composed of hydrochloric acid (HCl), potassium chloride (KCl), and sodium chloride (NaCl). The pH of gastric acid is typically between 1.5 and 3.5, making it a strong acid that helps to break down food by denaturing proteins and activating digestive enzymes.

The production of gastric acid is regulated by the enteric nervous system and several hormones. The primary function of gastric acid is to initiate protein digestion, activate pepsinogen into the active enzyme pepsin, and kill most ingested microorganisms. However, an excess or deficiency in gastric acid secretion can lead to various gastrointestinal disorders such as gastritis, ulcers, and gastroesophageal reflux disease (GERD).

Pancreatic neoplasms refer to abnormal growths in the pancreas that can be benign or malignant. The pancreas is a gland located behind the stomach that produces hormones and digestive enzymes. Pancreatic neoplasms can interfere with the normal functioning of the pancreas, leading to various health complications.

Benign pancreatic neoplasms are non-cancerous growths that do not spread to other parts of the body. They are usually removed through surgery to prevent any potential complications, such as blocking the bile duct or causing pain.

Malignant pancreatic neoplasms, also known as pancreatic cancer, are cancerous growths that can invade and destroy surrounding tissues and organs. They can also spread (metastasize) to other parts of the body, such as the liver, lungs, or bones. Pancreatic cancer is often aggressive and difficult to treat, with a poor prognosis.

There are several types of pancreatic neoplasms, including adenocarcinomas, neuroendocrine tumors, solid pseudopapillary neoplasms, and cystic neoplasms. The specific type of neoplasm is determined through various diagnostic tests, such as imaging studies, biopsies, and blood tests. Treatment options depend on the type, stage, and location of the neoplasm, as well as the patient's overall health and preferences.

Human Growth Hormone (HGH), also known as somatotropin, is a peptide hormone produced in the pituitary gland. It plays a crucial role in human development and growth by stimulating the production of another hormone called insulin-like growth factor 1 (IGF-1). IGF-1 promotes the growth and reproduction of cells throughout the body, particularly in bones and other tissues. HGH also helps regulate body composition, body fluids, muscle and bone growth, sugar and fat metabolism, and possibly heart function. It is essential for human development and continues to have important effects throughout life. The secretion of HGH decreases with age, which is thought to contribute to the aging process.

Motilin is a hormone that is produced and released by specialized cells called endocrine cells, which are located in the duodenum, which is the first part of the small intestine. Motilin plays an important role in regulating the movements of the gastrointestinal (GI) tract, also known as peristalsis.

Motilin stimulates the contraction of the smooth muscle in the GI tract, which helps to move food and other contents through the digestive system. It is particularly important for initiating the "housekeeper" wave, also known as the migrating motor complex (MMC), which occurs during periods of fasting and helps to clear out any remaining undigested material from the stomach and small intestine.

Motilin has been studied as a potential target for the treatment of gastroparesis, a condition in which the stomach is unable to empty properly due to weak or abnormal contractions of the smooth muscle. Motilin agonists, which are drugs that bind to and activate motilin receptors, have been shown to improve gastric emptying in some people with gastroparesis.

An islet cell adenoma is a rare, typically benign tumor that develops in the islets of Langerhans, which are clusters of hormone-producing cells in the pancreas. The islets of Langerhans contain several types of cells, including beta cells that produce insulin, alpha cells that produce glucagon, and delta cells that produce somatostatin.

Islet cell adenomas can cause various endocrine disorders depending on the type of hormone-producing cells involved. For example, if the tumor consists mainly of beta cells, it may secrete excessive amounts of insulin, leading to hypoglycemia (low blood sugar). Conversely, if the tumor is composed primarily of alpha cells, it may produce too much glucagon, resulting in hyperglycemia (high blood sugar) and a condition known as glucagonoma.

Islet cell adenomas are usually slow-growing and small but can become quite large in some cases. They are typically diagnosed through imaging tests such as CT scans or MRI, and hormone levels may be measured to determine the type of cells involved. Treatment options include surgical removal of the tumor, medication to manage hormonal imbalances, and, in rare cases, radiofrequency ablation or embolization.

The pituitary gland is a small, endocrine gland located at the base of the brain, in the sella turcica of the sphenoid bone. It is often called the "master gland" because it controls other glands and makes the hormones that trigger many body functions. The pituitary gland measures about 0.5 cm in height and 1 cm in width, and it weighs approximately 0.5 grams.

The pituitary gland is divided into two main parts: the anterior lobe (adenohypophysis) and the posterior lobe (neurohypophysis). The anterior lobe is further divided into three zones: the pars distalis, pars intermedia, and pars tuberalis. Each part of the pituitary gland has distinct functions and produces different hormones.

The anterior pituitary gland produces and releases several important hormones, including:

* Growth hormone (GH), which regulates growth and development in children and helps maintain muscle mass and bone strength in adults.
* Thyroid-stimulating hormone (TSH), which controls the production of thyroid hormones by the thyroid gland.
* Adrenocorticotropic hormone (ACTH), which stimulates the adrenal glands to produce cortisol and other steroid hormones.
* Follicle-stimulating hormone (FSH) and luteinizing hormone (LH), which regulate reproductive function in both males and females.
* Prolactin, which stimulates milk production in pregnant and lactating women.

The posterior pituitary gland stores and releases two hormones that are produced by the hypothalamus:

* Antidiuretic hormone (ADH), which helps regulate water balance in the body by controlling urine production.
* Oxytocin, which stimulates uterine contractions during childbirth and milk release during breastfeeding.

Overall, the pituitary gland plays a critical role in maintaining homeostasis and regulating various bodily functions, including growth, development, metabolism, and reproductive function.

The pyloric antrum is the distal part of the stomach, which is the last portion that precedes the pylorus and the beginning of the duodenum. It is a thickened, muscular area responsible for grinding and mixing food with gastric juices during digestion. The pyloric antrum also helps regulate the passage of chyme (partially digested food) into the small intestine through the pyloric sphincter, which controls the opening and closing of the pylorus. This region is crucial in the gastrointestinal tract's motor functions and overall digestive process.

Gastric mucosa refers to the innermost lining of the stomach, which is in contact with the gastric lumen. It is a specialized mucous membrane that consists of epithelial cells, lamina propria, and a thin layer of smooth muscle. The surface epithelium is primarily made up of mucus-secreting cells (goblet cells) and parietal cells, which secrete hydrochloric acid and intrinsic factor, and chief cells, which produce pepsinogen.

The gastric mucosa has several important functions, including protection against self-digestion by the stomach's own digestive enzymes and hydrochloric acid. The mucus layer secreted by the epithelial cells forms a physical barrier that prevents the acidic contents of the stomach from damaging the underlying tissues. Additionally, the bicarbonate ions secreted by the surface epithelial cells help neutralize the acidity in the immediate vicinity of the mucosa.

The gastric mucosa is also responsible for the initial digestion of food through the action of hydrochloric acid and pepsin, an enzyme that breaks down proteins into smaller peptides. The intrinsic factor secreted by parietal cells plays a crucial role in the absorption of vitamin B12 in the small intestine.

The gastric mucosa is constantly exposed to potential damage from various factors, including acid, pepsin, and other digestive enzymes, as well as mechanical stress due to muscle contractions during digestion. To maintain its integrity, the gastric mucosa has a remarkable capacity for self-repair and regeneration. However, chronic exposure to noxious stimuli or certain medical conditions can lead to inflammation, erosions, ulcers, or even cancer of the gastric mucosa.

Gastrointestinal (GI) hormones are a group of hormones that are secreted by cells in the gastrointestinal tract in response to food intake and digestion. They play crucial roles in regulating various physiological processes, including appetite regulation, gastric acid secretion, motility of the gastrointestinal tract, insulin secretion, and pancreatic enzyme release.

Examples of GI hormones include:

* Gastrin: Secreted by G cells in the stomach, gastrin stimulates the release of hydrochloric acid from parietal cells in the stomach lining.
* Ghrelin: Produced by the stomach, ghrelin is often referred to as the "hunger hormone" because it stimulates appetite and food intake.
* Cholecystokinin (CCK): Secreted by I cells in the small intestine, CCK promotes digestion by stimulating the release of pancreatic enzymes and bile from the liver. It also inhibits gastric emptying and reduces appetite.
* Gastric inhibitory peptide (GIP): Produced by K cells in the small intestine, GIP promotes insulin secretion and inhibits glucagon release.
* Secretin: Released by S cells in the small intestine, secretin stimulates the pancreas to produce bicarbonate-rich fluid that neutralizes stomach acid in the duodenum.
* Motilin: Secreted by MO cells in the small intestine, motilin promotes gastrointestinal motility and regulates the migrating motor complex (MMC), which is responsible for cleaning out the small intestine between meals.

These hormones work together to regulate digestion and maintain homeostasis in the body. Dysregulation of GI hormones can contribute to various gastrointestinal disorders, such as gastroparesis, irritable bowel syndrome (IBS), and diabetes.

Radiopharmaceuticals are defined as pharmaceutical preparations that contain radioactive isotopes and are used for diagnosis or therapy in nuclear medicine. These compounds are designed to interact specifically with certain biological targets, such as cells, tissues, or organs, and emit radiation that can be detected and measured to provide diagnostic information or used to destroy abnormal cells or tissue in therapeutic applications.

The radioactive isotopes used in radiopharmaceuticals have carefully controlled half-lives, which determine how long they remain radioactive and how long the pharmaceutical preparation remains effective. The choice of radioisotope depends on the intended use of the radiopharmaceutical, as well as factors such as its energy, range of emission, and chemical properties.

Radiopharmaceuticals are used in a wide range of medical applications, including imaging, cancer therapy, and treatment of other diseases and conditions. Examples of radiopharmaceuticals include technetium-99m for imaging the heart, lungs, and bones; iodine-131 for treating thyroid cancer; and samarium-153 for palliative treatment of bone metastases.

The use of radiopharmaceuticals requires specialized training and expertise in nuclear medicine, as well as strict adherence to safety protocols to minimize radiation exposure to patients and healthcare workers.

Pentagastrin is a synthetic polypeptide hormone that stimulates the release of gastrin and hydrochloric acid from the stomach. It is used diagnostically to test for conditions such as Zollinger-Ellison syndrome, a rare disorder in which tumors in the pancreas or duodenum produce excessive amounts of gastrin, leading to severe ulcers and other digestive problems.

Pentagastrin is typically administered intravenously, and its effects are monitored through blood tests that measure gastric acid secretion. It is a potent stimulant of gastric acid production, and its use is limited to diagnostic purposes due to the risk of adverse effects such as nausea, flushing, and increased heart rate.

Secretin is a hormone that is produced and released by the S cells in the duodenum, which is the first part of the small intestine. It is released in response to the presence of acidic chyme (partially digested food) entering the duodenum from the stomach. Secretin stimulates the pancreas to produce bicarbonate-rich alkaline secretions, which help neutralize the acidity of the chyme and create an optimal environment for enzymatic digestion in the small intestine.

Additionally, secretin also promotes the production of watery fluids from the liver, which aids in the digestion process. Overall, secretin plays a crucial role in maintaining the pH balance and facilitating proper nutrient absorption in the gastrointestinal tract.

Antineoplastic agents, hormonal, are a class of drugs used to treat cancers that are sensitive to hormones. These agents work by interfering with the production or action of hormones in the body. They can be used to slow down or stop the growth of cancer cells and may also help to relieve symptoms caused by the spread of cancer.

Hormonal therapies can work in one of two ways: they can either block the production of hormones or prevent their action on cancer cells. For example, some hormonal therapies work by blocking the action of estrogen or testosterone, which are hormones that can stimulate the growth of certain types of cancer cells.

Examples of hormonal agents used to treat cancer include:

* Aromatase inhibitors (such as letrozole, anastrozole, and exemestane), which block the production of estrogen in postmenopausal women
* Selective estrogen receptor modulators (such as tamoxifen and raloxifene), which block the action of estrogen on cancer cells
* Luteinizing hormone-releasing hormone agonists (such as leuprolide, goserelin, and triptorelin), which block the production of testosterone in men
* Antiandrogens (such as bicalutamide, flutamide, and enzalutamide), which block the action of testosterone on cancer cells

Hormonal therapies are often used in combination with other treatments, such as surgery or radiation therapy. They may be used to shrink tumors before surgery, to kill any remaining cancer cells after surgery, or to help control the spread of cancer that cannot be removed by surgery. Hormonal therapies can also be used to relieve symptoms and improve quality of life in people with advanced cancer.

It's important to note that hormonal therapies are not effective for all types of cancer. They are most commonly used to treat breast, prostate, and endometrial cancers, which are known to be sensitive to hormones. Hormonal therapies may also be used to treat other types of cancer in certain situations.

Like all medications, hormonal therapies can have side effects. These can vary depending on the specific drug and the individual person. Common side effects of hormonal therapies include hot flashes, fatigue, mood changes, and sexual dysfunction. Some hormonal therapies can also cause more serious side effects, such as an increased risk of osteoporosis or blood clots. It's important to discuss the potential risks and benefits of hormonal therapy with a healthcare provider before starting treatment.

Virulence factors in Bordetella pertussis, the bacterium that causes whooping cough, refer to the characteristics or components of the organism that contribute to its ability to cause disease. These virulence factors include:

1. Pertussis Toxin (PT): A protein exotoxin that inhibits the immune response and affects the nervous system, leading to the characteristic paroxysmal cough of whooping cough.
2. Adenylate Cyclase Toxin (ACT): A toxin that increases the levels of cAMP in host cells, disrupting their function and contributing to the pathogenesis of the disease.
3. Filamentous Hemagglutinin (FHA): A surface protein that allows the bacterium to adhere to host cells and evade the immune response.
4. Fimbriae: Hair-like appendages on the surface of the bacterium that facilitate adherence to host cells.
5. Pertactin (PRN): A surface protein that also contributes to adherence and is a common component of acellular pertussis vaccines.
6. Dermonecrotic Toxin: A toxin that causes localized tissue damage and necrosis, contributing to the inflammation and symptoms of whooping cough.
7. Tracheal Cytotoxin: A toxin that damages ciliated epithelial cells in the respiratory tract, impairing mucociliary clearance and increasing susceptibility to infection.

These virulence factors work together to enable Bordetella pertussis to colonize the respiratory tract, evade the host immune response, and cause the symptoms of whooping cough.

Pertussis toxin is an exotoxin produced by the bacterium Bordetella pertussis, which is responsible for causing whooping cough in humans. This toxin has several effects on the host organism, including:

1. Adenylyl cyclase activation: Pertussis toxin enters the host cell and modifies a specific G protein (Gαi), leading to the continuous activation of adenylyl cyclase. This results in increased levels of intracellular cAMP, which disrupts various cellular processes.
2. Inhibition of immune response: Pertussis toxin impairs the host's immune response by inhibiting the migration and function of immune cells like neutrophils and macrophages. It also interferes with antigen presentation and T-cell activation, making it difficult for the body to clear the infection.
3. Increased inflammation: The continuous activation of adenylyl cyclase by pertussis toxin leads to increased production of proinflammatory cytokines, contributing to the severe coughing fits and other symptoms associated with whooping cough.

Pertussis toxin is an essential virulence factor for Bordetella pertussis, and its effects contribute significantly to the pathogenesis of whooping cough. Vaccination against pertussis includes inactivated or genetically detoxified forms of pertussis toxin, which provide immunity without causing disease symptoms.

Bombesin is a type of peptide that occurs naturally in the body. It is a small protein-like molecule made up of amino acids, and it is involved in various physiological processes, including regulating appetite and digestion. Bombesin was first discovered in the skin of a frog species called Bombina bombina, hence its name. In the human body, bombesin-like peptides are produced by various tissues, including the stomach and brain. They bind to specific receptors in the body, triggering a range of responses, such as stimulating the release of hormones and increasing gut motility. Bombesin has been studied for its potential role in treating certain medical conditions, including cancer, although more research is needed to establish its safety and efficacy.

Malignant carcinoid syndrome is a complex of symptoms that occur in some people with malignant tumors (carcinoids) that secrete large amounts of hormone-like substances, particularly serotonin. These symptoms can include flushing of the face and upper body, diarrhea, rapid heartbeat, difficulty breathing, and abdominal pain and distention. In addition, these individuals may have chronic inflammation of the heart valves (endocarditis) leading to heart failure. It is important to note that not all people with carcinoid tumors will develop malignant carcinoid syndrome, but those who do require specific treatment for their symptoms and hormonal imbalances.

Secretory rate refers to the amount or volume of a secretion produced by a gland or an organ over a given period of time. It is a measure of the productivity or activity level of the secreting structure. The secretory rate can be quantified for various bodily fluids, such as saliva, sweat, digestive enzymes, hormones, or milk, depending on the context and the specific gland or organ being studied.

In clinical settings, measuring the secretory rate might involve collecting and analyzing samples over a certain duration to estimate the production rate of the substance in question. This information can be helpful in diagnosing conditions related to impaired secretion, monitoring treatment responses, or understanding the physiological adaptations of the body under different circumstances.

Cholecystokinin (CCK) is a hormone that is produced in the duodenum (the first part of the small intestine) and in the brain. It is released into the bloodstream in response to food, particularly fatty foods, and plays several roles in the digestive process.

In the digestive system, CCK stimulates the contraction of the gallbladder, which releases bile into the small intestine to help digest fats. It also inhibits the release of acid from the stomach and slows down the movement of food through the intestines.

In the brain, CCK acts as a neurotransmitter and has been shown to have effects on appetite regulation, mood, and memory. It may play a role in the feeling of fullness or satiety after eating, and may also be involved in anxiety and panic disorders.

CCK is sometimes referred to as "gallbladder-stimulating hormone" or "pancreozymin," although these terms are less commonly used than "cholecystokinin."

Neuropeptides are small protein-like molecules that are used by neurons to communicate with each other and with other cells in the body. They are produced in the cell body of a neuron, processed from larger precursor proteins, and then transported to the nerve terminal where they are stored in secretory vesicles. When the neuron is stimulated, the vesicles fuse with the cell membrane and release their contents into the extracellular space.

Neuropeptides can act as neurotransmitters or neuromodulators, depending on their target receptors and the duration of their effects. They play important roles in a variety of physiological processes, including pain perception, appetite regulation, stress response, and social behavior. Some neuropeptides also have hormonal functions, such as oxytocin and vasopressin, which are produced in the hypothalamus and released into the bloodstream to regulate reproductive and cardiovascular function, respectively.

There are hundreds of different neuropeptides that have been identified in the nervous system, and many of them have multiple functions and interact with other signaling molecules to modulate neural activity. Dysregulation of neuropeptide systems has been implicated in various neurological and psychiatric disorders, such as chronic pain, addiction, depression, and anxiety.

Gastrointestinal (GI) neoplasms refer to abnormal growths in the gastrointestinal tract, which can be benign or malignant. The gastrointestinal tract includes the mouth, esophagus, stomach, small intestine, large intestine, rectum, and anus.

Benign neoplasms are non-cancerous growths that do not invade nearby tissues or spread to other parts of the body. They can sometimes be removed completely and may not cause any further health problems.

Malignant neoplasms, on the other hand, are cancerous growths that can invade nearby tissues and organs and spread to other parts of the body through the bloodstream or lymphatic system. These types of neoplasms can be life-threatening if not diagnosed and treated promptly.

GI neoplasms can cause various symptoms, including abdominal pain, bloating, changes in bowel habits, nausea, vomiting, weight loss, and anemia. The specific symptoms may depend on the location and size of the neoplasm.

There are many types of GI neoplasms, including adenocarcinomas, gastrointestinal stromal tumors (GISTs), lymphomas, and neuroendocrine tumors. The diagnosis of GI neoplasms typically involves a combination of medical history, physical examination, imaging studies, and biopsy. Treatment options may include surgery, radiation therapy, chemotherapy, targeted therapy, or immunotherapy.

Galanin is a neuropeptide, which is a type of small protein molecule that functions as a neurotransmitter or neuromodulator in the nervous system. It is widely distributed throughout the central and peripheral nervous systems of vertebrates and plays important roles in various physiological functions, including modulation of pain perception, regulation of feeding behavior, control of circadian rhythms, and cognitive processes such as learning and memory.

Galanin is synthesized from a larger precursor protein called preprogalanin, which is cleaved into several smaller peptides, including galanin itself, galanin message-associated peptide (GMAP), and alarin. Galanin exerts its effects by binding to specific G protein-coupled receptors, known as the galanin receptor family, which includes three subtypes: GalR1, GalR2, and GalR3. These receptors are widely expressed in various tissues and organs, including the brain, spinal cord, gastrointestinal tract, pancreas, and cardiovascular system.

Galanin has been implicated in several pathological conditions, such as chronic pain, depression, anxiety, epilepsy, and neurodegenerative disorders like Alzheimer's disease and Parkinson's disease. As a result, there is ongoing research into the development of galanin-based therapies for these conditions.

Cysteamine is a medication and a naturally occurring aminothiol compound, which is composed of the amino acid cysteine and a sulfhydryl group. It has various uses in medicine, including as a treatment for cystinosis, a rare genetic disorder that causes an accumulation of cystine crystals in various organs and tissues. Cysteamine works by reacting with cystine to form a compound that can be more easily eliminated from the body. It is available in oral and topical forms and may also be used for other indications, such as treating lung diseases and radiation-induced damage.

Insulinoma is a rare type of neuroendocrine tumor that originates from the beta cells of the pancreatic islets (islets of Langerhans). These tumors produce and secrete excessive amounts of insulin, leading to hypoglycemia (low blood sugar levels) even when the person hasn't eaten for a while. Insulinomas are typically slow-growing and benign (noncancerous), but about 10% of them can be malignant (cancerous) and may spread to other parts of the body. Common symptoms include sweating, confusion, dizziness, and weakness due to low blood sugar levels. The diagnosis is often confirmed through imaging tests like CT scans or MRI, and measuring insulin and C-peptide levels in the blood during a fasting test. Treatment usually involves surgical removal of the tumor.

Messenger RNA (mRNA) is a type of RNA (ribonucleic acid) that carries genetic information copied from DNA in the form of a series of three-base code "words," each of which specifies a particular amino acid. This information is used by the cell's machinery to construct proteins, a process known as translation. After being transcribed from DNA, mRNA travels out of the nucleus to the ribosomes in the cytoplasm where protein synthesis occurs. Once the protein has been synthesized, the mRNA may be degraded and recycled. Post-transcriptional modifications can also occur to mRNA, such as alternative splicing and addition of a 5' cap and a poly(A) tail, which can affect its stability, localization, and translation efficiency.

The somatostatin receptors are G protein-coupled receptors. Somatostatin receptor subtypes in humans are sstr1, 2A, 2 B, 3, 4 ... Somatostatin receptor antagonists (or somatostatin inhibitors) are a class of chemical compounds that work by imitating the ... Somatostatin analogue therapy uses longer-acting agonists than the endogenous somatostatin to extend the antiproliferative ... The nomenclature of the somatostatin receptor antagonists is also based on this order. The structure of somatostatin receptor ...
The somatostatin receptors are G protein-coupled receptors. Somatostatin receptor subtypes in humans include sstr1, 2A, 2 B, 3 ... Somatostatin receptor antagonists (or somatostatin inhibitors) are a class of chemical compounds that work by imitating the ... Somatostatin analogue therapy uses longer-acting agonists than the endogenous somatostatin to extend the antiproliferative ... It is a non-selective somatostatin receptor antagonist, inhibiting the effects of somatostatin on target cells in the ...
Pasireotide is somatostatin analog with a 40-fold increased affinity to somatostatin receptor 5 compared to other somatostatin ... In addition, somatostatin release from delta cells can act in a paracrine manner. In the stomach, somatostatin acts directly on ... Somatostatin release is inhibited by the Vagus nerve. In the anterior pituitary gland, the effects of somatostatin are: ... "Entrez Gene: Somatostatin". Shen LP, Pictet RL, Rutter WJ (August 1982). "Human somatostatin I: sequence of the cDNA". ...
Gomez S, Gluschankof P, Morel A, Cohen P (September 1985). "The somatostatin-28 convertase of rat brain cortex is associated ... Gluschankof P, Gomez S, Morel A, Cohen P (July 1987). "Enzymes that process somatostatin precursors. A novel endoprotease that ... cleaves before the arginine-lysine doublet is involved in somatostatin-28 convertase activity of rat brain cortex". The Journal ...
As of June 2020[update], octreotide (Mycapssa) is the first and only oral somatostatin analog (SSA) approved by the FDA. It is ... Since octreotide resembles somatostatin in physiological activities, it can: inhibit secretion of many hormones, such as ... Mycapssa is the first and only oral somatostatin analog (SSA) approved by the FDA. Octreotide helps in management of the ... It was first synthesized in 1979 by the chemist Wilfried Bauer, and binds predominantly to the somatostatin receptors SSTR2 and ...
However, while somatostatin is quickly broken down in the body (within minutes), lanreotide has a much longer half-life, and ... It is a long-acting analogue of somatostatin, like octreotide. Lanreotide (as lanreotide acetate) is manufactured by Ipsen. It ... Susini C, Buscail L (2006). "Rationale for the use of somatostatin analogs as antitumor agents". Ann Oncol. 17 (12): 1733-42. ... Lanreotide also shows activity against non-endocrine tumors, and, along with other somatostatin analogues, is being studied as ...
... and the group became the first to successfully express a human gene in bacteria when they produced the hormone somatostatin in ... "Expression in Escherichia coli of a chemically synthesized gene for the hormone somatostatin". Science. 198 (4321): 1056-1063. ... "In January 1976, 28-year-old venture capitalist Robert Swanson entered the picture. A successful cold-call to Boyer's lab led ... Retrieved August 28, 2017. Itakura, K.; Hirose, T.; Crea, R.; Riggs, A. D.; Heyneker, H. L.; Bolivar, F.; Boyer, H. W. (1977 ...
Zabel M (December 1984). "Ultrastructural localization of calcitonin, somatostatin and serotonin in parafollicular cells of rat ... somatostatin or CGRP. They may also have a role in regulating thyroid hormones production locally, as they express thyrotropin- ... 142 (20): 3519-28. doi:10.1242/dev.126581. PMC 4631767. PMID 26395490. Melmed S, Polonsky KS, Larsen PR, Kronenberg HM (2011). ...
Dörflinger U, Pscherer A, Moser M, Rümmele P, Schüle R, Buettner R (May 1999). "Activation of somatostatin receptor II ...
"The 86-kDa subunit of autoantigen Ku is a somatostatin receptor regulating protein phosphatase-2A activity". J. Biol. Chem. 269 ... 33 (28): 8548-57. doi:10.1021/bi00194a021. PMID 8031790. Taccioli GE, Gottlieb TM, Blunt T, Priestley A, Demengeot J, Mizuta R ... 1819-28. doi:10.1093/emboj/17.6.1819. PMC 1170529. PMID 9501103. "Entrez Gene: XRCC6 X-ray repair complementing defective ...
"The expression of the phosphotyrosine phosphatase DEP-1/PTPeta dictates the responsivity of glioma cells to somatostatin ... 279 (28): 29004-12. doi:10.1074/jbc.M403573200. PMID 15123617. v t e (Articles with short description, Short description ...
... somatostatin (SST), somatostatin receptor 2 (SSTR2)as well as a variety of other somatostatin receptors, spermine synthase (SMS ... All of the somatostatin related proteins are involved in the inhibition of hormones. There is very little known about TMEM132C ... Feb-Apr 2002). "Drug design at peptide receptors: somatostatin receptor ligands". Journal of Molecular Neuroscience. 18 (1-2): ... 31 (28): 3346-56. doi:10.1038/onc.2011.505. PMC 3298579. PMID 22105367. Naba A, Clauser KR, Hoersch S, Liu H, Carr SA, Hynes RO ...
2003). "Expression of somatostatin, cortistatin, and somatostatin receptors in human monocytes, macrophages, and dendritic ... 2003). "Cortistatin rather than somatostatin as a potential endogenous ligand for somatostatin receptors in the human immune ... and which has a strong structural similarity to somatostatin. Unlike somatostatin, when infused into the brain, it enhances ... It binds to all known somatostatin receptors, and shares many pharmacological and functional properties with somatostatin, ...
... somatostatin receptor-positive (SSTR+), neuroendocrine tumours of gastroenteric or pancreatic origin (GEP-NET)". EU Clinical ... "Phase I trial of 90Y-DOTATOC therapy in children and young adults with refractory solid tumors that express somatostatin ... Somatostatin inhibitors, Macrocycles, Cyclic peptides, Multiple Chemboxes, DOTA (chelator) derivatives, All stub articles, ... 28 (10): 1652-9. doi:10.1200/JCO.2009.22.8585. PMC 4872330. PMID 20194865. "The therapeutic n.c.a. 177Lu-Edotreotide (Solucin ...
The combination of somatostatin receptor and FDG PET imaging is able to quantify somatostatin receptor cell surface (SSTR) ... Neuroendocrine tumours express somatostatin receptors providing a unique target for imaging. Octreotide is a synthetic ... This is a highly targeted and effective therapy with minimal side effects in tumors with high levels of somatostatin cell ... A consensus review has reported on the use of somatostatin analogs for GEP-NETs. These medications may also anatomically ...
Some evidence also suggests that somatostatin can be an effective treatment with respect to reducing closure time and improving ... "Systematic review and meta-analysis of the role of somatostatin and its analogues in the treatment of enterocutaneous fistula ... The median time to definitive repair from fistula onset was 6 months (range 1 day to 28 months). The 6-month time course is ...
"Expanded Access Protocol for Therapeutic Use of 177Lu-DOTA0-Tyr3-Octreotate in Patients With Inoperable, Somatostatin Receptor ... 2016-09-28. Retrieved 2017-02-10. McCormack, Kevin (December 19, 2016). "'Right To Try' laws called 'Right To Beg' by Stem Cell ... Positive, Midgut Carcinoid Tumors, Progressive Under Somatostatin Analogue Therapy". ClinicalTrials.gov. 2017-02-17. Retrieved ...
Some of the tumors express somatostatin receptors and may be located by octreotide scanning. A phosphaturic mesenchymal tumor ... Tumors that express somatostatin receptors may respond to treatment with octreotide. If hypophosphatemia persists despite ... which research reflects as being between 2.5 and 28 years. Tumor-induced osteomalacia is usually referred to as a ...
... approved telotristat ethyl in combination with somatostatin analog (SSA) therapy for the treatment of adults with diarrhea ... "FDA Approves Xermelo for Carcinoid Syndrome Diarrhea" (Press release). U.S. Food and Drug Administration (FDA). February 28, ... On February 28, 2017, the U.S. Food and Drug Administration (FDA) ...
Expression of somatostatin receptors in inflammatory lesions and diagnostic value of somatostatin receptor scintigraphy in ... Somatostatin receptor scintigraphy (SRS) and therapy of neuroendocrine diseases (NET) with radionuclides (PRRT) Benign and ... Additional lesions detected in therapeutic scans with 177Lu-DOTATATE reflect higher affinity of 177Lu-DOTATATE for somatostatin ... 2001 Jun 28;344(26):2030-1. PMID 11430342. Dimou E, Booij J, Rodrigues M, Prosch H, Attems J, Knoll P, Zajicek B, Dudczak R, ...
1984). "High-resolution chromosomal localization of human genes for amylase, proopiomelanocortin, somatostatin, and a DNA ... 28 (2): 263-70. doi:10.1016/0378-1119(84)90265-8. PMID 6610603. Seyama K, Nukiwa T, Takahashi K, et al. (1994). "Amylase mRNA ...
... was first described in 1987 as a cAMP-responsive transcription factor regulating the somatostatin gene. Genes whose ... "Binding of a nuclear protein to the cyclic-AMP response element of the somatostatin gene". Nature. 328 (6126): 175-178. Bibcode ... 28 (8): 436-45. doi:10.1016/j.tins.2005.06.005. PMID 15982754. S2CID 6480593. Kandel, Eric R. (14 May 2012). "The molecular ... 28 (8): 436-445. doi:10.1016/j.tins.2005.06.005. PMID 15982754. S2CID 6480593. Altarejos, Judith Y.; Montminy, Marc (March 2011 ...
D-cells - D-cells secrete somatostatin. Somatostatin suppresses the release of hormones from the digestive tract. Fundic gland ... Minor changes: 28 December 2020 Pocock, Gillian (2006). Human Physiology (3rd ed.). Oxford University Press. p. 388. ISBN 978-0 ...
This region has been shown to aid in the production of somatostatin and research shows that neurons releasing somatostatin are ... The rostral region aids in the production of both somatostatin and thyroid releasing hormone. The intermediate portion aids in ... There is thought to be a differential level of secretion of somatostatin between males and females by the periventricular ... Murray; Simonian (2001). "Correlation of hypothalamic somatostatin mRNA expression and peptide content with secretion: sexual ...
These endocrine cells include D cells, which release somatostatin, responsible for shutting off acid secretion. (There is a ... 28 (6): 429-34. doi:10.1007/s002470050377. PMID 9634457. Lin, Hsien-Ping; Lin, Yu-Chiang; Kuo, Chen-Yun (2015). "Adult ...
Somatostatin and octreotide, while recommended for varicial bleeding, have not been found to be of general use for non variceal ... Gøtzsche, PC; Hróbjartsson, A (2008-07-16). Gøtzsche, Peter C (ed.). "Somatostatin analogues for acute bleeding oesophageal ... Wu, LC; Cao, YF; Huang, JH; Liao, C; Gao, F (2010-05-28). "High-dose vs low-dose proton pump inhibitors for upper ... Wang, J; Bao, YX; Bai, M; Zhang, YG; Xu, WD; Qi, XS (28 October 2013). "Restrictive vs liberal transfusion for upper ...
SHH Somatostatin analog, resistance to; 102200; SSTR5 Sorsby fundus dystrophy; 136900; TIMP3 Sotos syndrome; 117550; NSD1 ... autosomal dominant 28; 608641; GRHL2 Deafness, autosomal dominant 2A; 600101; KCNQ4 Deafness, autosomal dominant 2B; 612644; ... autosomal recessive 28; 609823; TRIOBP Deafness, autosomal recessive 3; 600316; MYO15A Deafness, autosomal recessive 30; 607101 ... TBP Spinocerebellar ataxia 28; 610246; AFG3L2 Spinocerebellar ataxia 31; 117210; BEAN Spinocerebellar ataxia 8; 608768; ATXN8OS ...
The release of CCK is also inhibited by somatostatin and pancreatic peptide. Trypsin, a protease released by pancreatic acinar ... 9 (1): 1-28. ISSN 0892-0915. PMID 8828002. Ma, Yihe; Giardino, William J. (1 September 2022). "Neural circuit mechanisms of the ... ISBN 978-0-323-10085-4. Bowen R (28 January 2001). "Cholecystokinin". Colorado State University. Archived from the original on ...
March 2006). "Human adipose tissue-derived mesenchymal stem cells differentiate into insulin, somatostatin, and glucagon ... 21 (1-2): 41-5. doi:10.1023/B:GLYC.0000043746.77504.28. PMID 15467397. S2CID 25818208. Ganat YM, Silbereis J, Cave C, et al. ( ... 50 (2-3): 217-28. doi:10.1016/0925-4773(94)00338-N. PMID 7619732. (All articles with dead external links, Articles with dead ... 41 (1-2): 19-28. doi:10.1290/0502010.1. PMID 15926856. S2CID 1995302. Przyborski SA (2001). "Isolation of human embryonal ...
Initial human studies with 44Sc-DOTATOC PET/CT imaging of somatostatin receptor positive liver metastases in a patient at early ... 2023-02-28). "Engineering a modular 44Ti/44Sc generator: eluate evaluation in preclinical models and estimation of human ...
There is a group of somatostatin receptors called the somatostatin receptor family. All of the members of the somatostatin ... and somatostatin receptor 2b (SSTR2B). In a rodent, somatostatin receptor 2a is longer compared to the shorter somatostatin ... For all somatostatin inhibitors, somatostatin-14 and -28 work by binding to the receptor with the help of a G-protein. This ... Somatostatin receptor 2a has a shorter transcript, but is longer than somatostatin receptor 2b and has a unique C- terminus ...
Somatostatin receptor type 5 is a protein that in humans is encoded by the SSTR5 gene. Somatostatin acts at many sites to ... 2001). "Mutation of somatostatin receptor type 5 in an acromegalic patient resistant to somatostatin analog treatment". J. Clin ... somatostatin receptor type 5) with preferential affinity for somatostatin-28". Mol. Pharmacol. 45 (3): 417-27. PMID 7908405. ... somatostatin+receptor+5 at the U.S. National Library of Medicine Medical Subject Headings (MeSH) This article incorporates text ...
1994). "Characterization of somatostatin transactivating factor-1, a novel homeobox factor that stimulates somatostatin ... 2000). "Pancreatic homeodomain transcription factor IDX1/IPF1 expressed in developing brain regulates somatostatin gene ... 28 (1): 125-6. doi:10.1006/geno.1995.1120. PMID 7590740. Wright, C. V., Schnegelsberg, P., & De Robertis, E. M. (1989). XlHbox ... 28 (1): 125-6. doi:10.1006/geno.1995.1120. PMID 7590740. Inoue H, Riggs AC, Tanizawa Y, et al. (1996). "Isolation, ...
Itakura successfully synthesized the gene for somatostatin. Production of somatostatin, a hormone produced in the human brain, ... He then inserted the gene for somatostatin into E. coli. This was the first demonstration of a foreign gene inserted into E. ... "Expression in Escherichia coli of a chemically synthesized gene for the hormone somatostatin". Science. 198 (4321): 1056-63. ... 28 October 1976). "Synthetic lacoperator DNA is functional in vivo". Nature. 263 (5580): 748-752. Bibcode:1976Natur.263..748H. ...
... somatostatin receptor ligands- preoperatively) and postoperative imaging assessment. For Cushing's disease there is surgery to ... Retrieved 28 August 2015. Wendy (2013). Medical-surgical nursing : an integrated approach (3rd ed.). Clifton Park, NY: Delmar ... Retrieved 28 August 2015. "Cushing's Syndrome". www.niddk.nih.gov. Retrieved 2015-08-25. Laws, Edward; Ezzat, Shereen; Asa, ...
The results found by the researchers have defined a role for specific hippocampal inhibitory cells (somatostatin expressing ... "Hippocampal Somatostatin Interneurons Control the Size of Neuronal Memory Ensembles". Neuron. 89 (5): 1074-1085. doi:10.1016/j. ... Ryan, T. J.; Roy, D. S.; Pignatelli, M.; Arons, A.; Tonegawa, S. (28 May 2015). "Engram cells retain memory under retrograde ...
Receptor Agonists products for your research including Somatostatin Receptor Agonists Small Molecules and Somatostatin Receptor ...
The somatostatin receptors are G protein-coupled receptors. Somatostatin receptor subtypes in humans are sstr1, 2A, 2 B, 3, 4 ... Somatostatin receptor antagonists (or somatostatin inhibitors) are a class of chemical compounds that work by imitating the ... Somatostatin analogue therapy uses longer-acting agonists than the endogenous somatostatin to extend the antiproliferative ... The nomenclature of the somatostatin receptor antagonists is also based on this order. The structure of somatostatin receptor ...
Somatostatin acetate is commonly used in the clinical treatment of severe acute esophageal varicose hemorrhage, severe acute ... Home » Shop » 15-28-Somatostatin-28 38916-34-6. 15-28-Somatostatin-28 38916-34-6. Share: Facebook Twitter LinkedIn Telegram ... Be the first to review "15-28-Somatostatin-28 38916-34-6" Cancel reply. Your email address will not be published. Required ...
Comparison of the gastric exocrine inhibitory activities and plasma kinetics of somatostatin-28 and somatostatin-14 in cats. / ... Comparison of the gastric exocrine inhibitory activities and plasma kinetics of somatostatin-28 and somatostatin-14 in cats. In ... Dive into the research topics of Comparison of the gastric exocrine inhibitory activities and plasma kinetics of somatostatin- ... Comparison of the gastric exocrine inhibitory activities and plasma kinetics of somatostatin-28 and somatostatin-14 in cats. ...
... tumors that arise from the pancreas or the gastrointestinal tract and are characterized by excessive secretion of somatostatin ... Use of the somatostatin analogue octreotide to localise and manage somatostatin-producing tumours. Gut. 1998 Jun. 42(6):792-4. ... Somatostatin is a cyclic peptide present in both 14-amino acid and 28-amino acid forms. It acts in both an endocrine and a ... Somatostatin-receptor imaging in the localization of endocrine tumors. N Engl J Med. 1990 Nov 1. 323(18):1246-9. [QxMD MEDLINE ...
Somatostatin Analog Intravenous, Subcutaneous. Jan. 28, 2008 Oct. 31, 2011 In Use. ... Somatostatin Analog Intravenous, Subcutaneous. Jan. 28, 2008 Oct. 31, 2011 In Use. ... June 28, 2010 Dec. 12, 2011 No Longer Used. 42291-0373-90. 42291-0373 Letrozole. Letrozole. Hormonal Therapy Aromatase ... 28, 2012 In Use. 55390-0122-10. 55390-0122 Cyclosporine. Cyclosporine. Ancillary Therapy Immunomodulator Calcineurin Inhibitor ...
A61K38/17-Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; ... A61K38/16-Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof ... 28,31-undecazacyclotritriacontane-2,5,8,11,14,17 Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H]( ...
These CeA GABA neurons express dynorphin, somatostatin and/or corticotropin releasing hormone. We find that the efficacy of ... We describe a novel pathway, consisting of inhibition by dynorphin, somatostatin and corticotropin-releasing hormone expressing ... every other day for 28 days. analysis of the brains of these rats clearly showed that this effect was mediated by mu-opioid ...
Somatostatin (Growth hormone-inhibiting hormone, Somatotropin release-inhibiting hormone). * Overview: somatostatin * 14- and ... Somatostatin analog -- longer plasma elimination half-life (80 minutes). * , 40X more potent than somatostatin in inhibiting ... Pancreatic D cells (somatostatin-secreting) are involved in insulin and glucagon regulation (paracrine action) ... Relatively small effect on insulin secretion (compared to somatostatin) allows clinical use without concern for inducing ...
1984) Somatostatin 28(1-14) immunoreactivity in primary afferent neurons of the rat spinal cord. Neurosci Lett 46:161-166. ... 1996) Somatostatin-containing cells in the rat hippocampus: connectivity and heterogeneity. Eur J Neurosci [Suppl] 9:176. ... 1982) Somatostatin-like immunoreactive neurons in the hippocampus: an immunocytochemical study in the rat. Neurosci Lett 34:259 ... 1995) Somatostatin neurons are a subpopulation of GABA neurons in the rat dentate gyrus: evidence from colocalization of pre- ...
Somatostatin:metabolism,. OBJECTIVE: Somatostatin receptor (SSTR) expression constitutes a pivotal cornerstone for accurate ... Regional differences in somatostatin receptor 2 (SSTR2) immunoreactivity is coupled to level of bowel invasion in small ... Fotouhi O, Zedenius J, Höög A, Juhlin C. Regional differences in somatostatin receptor 2 (SSTR2) immunoreactivity is coupled to ... concomitant administration of Somatostatin / Octreotide, Retinoids, Vit E, Vit D3, Vit C, Melatonin, D2 R agonists (Di Bella ...
PRRT and radiolabeled somatostatin (SST) peptide analogues are highly effective treatment agents. Somatostatin is in the form ... Molecular biology of somatostatin receptors. Endocrine Reviews. 1995;. 16. (4):427-442. DOI: 10.1210/edrv-16-4-427. ... Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors. ... Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype- ...
Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings. Semin Nucl Med. 2002;32:133- ... This is best illustrated in the case of peptides that target the somatostatin receptor found on neuroendocrine tumors. The ... Pauwels S, Barone R, Walrand S. Practical dosimetry of peptide receptor radionuclide therapy with 90Y-labeled somatostatin ...
Somatostatin-28 (sheep). C137H207N41O39S3. ... C92H150N28O29. 114471-18-0. Nesiritide acetate. C143H244N50O42S ... C28H54N8O7. 192387-38-5. L-Alanylglycyl-L-alpha-Glutamylglycyl-L-Leucyl-L-Asparaginyl-L-Seryl-L-Glutaminyl-L-Phenylalanyl-L- ... 186142-28-9. L-Seryl-L-alpha-Glutamyl-L-Valyl-L-Asparaginyl-L-Leucyl-L-alpha-Aspartyl-L-Alanyl-L-alpha-Glutamyl-L-Phenylalanyl- ... 59401-28-4. Trp-His-Trp-Leu-Gln-Leu-Lys-Pro-Gly-Gln-Pro-Met-Tyr. C82H114N20O17S. ...
Gonzalez-Rodriguez, M. et al. Somatostatin and astroglial involvement in the human limbic system in Alzheimers disease. Int. J ... Somatostatin (SST), a well-known neuropeptide, is expressed throughout the brain in two different isoforms, SST-14 and SST-28. ... Saito, T. et al. Somatostatin regulates brain amyloid beta peptide Abeta42 through modulation of proteolytic degradation. Nat. ... Song, Y. H., Yoon, J. & Lee, S. H. The role of neuropeptide somatostatin in the brain and its application in treating ...
Effect on motilin and somatostatin blood levels. Dig. Dis Sci. 1990, 35, 327-332. [Google Scholar] [CrossRef] ... Itoh, H.; Katagiri, F.; Ikawa, K.; Takeyama, M. Effects of domperidone on human plasma levels of motilin, somatostatin, gastrin ... Chan-Palay, V.; Ito, M.; Tongroach, P.; Sakurai, M.; Palay, S. Inhibitory effects of motilin, somatostatin, [leu]enkephalin, [ ... somatostatin and their receptor genes and risk of biliary tract cancers and stones in Shanghai, China. Meta Gene 2014, 2, 418- ...
Reubi JC, Chayvialle JA, Franc B, Cohen R, Calmettes C, Modigliani E. Somatostatin receptors and somatostatin content in ... In vivo somatostatin receptor imaging in medullary thyroid carcinoma. J Clin Endocrinol Metab. 1993;76:1413-1417. ... Somatostatin receptor-mediated imaging and therapy: basic science, current knowledge, limitations and future perspectives. Eur ... 99mTc]Demotate, a new 99mTc-based [Tyr3]octreotate analogue for the detection of somatostatin receptor-positive tumours: ...
2008) Somatostatin receptor subtype 4 couples to the M-current to regulate seizures. The Journal of Neuroscience : the Official ... 2010) Somatostatin signaling in neuronal cilia is critical for object recognition memory. The Journal of Neuroscience : the ... 2002) Somatostatin depresses long-term potentiation and Ca2+ signaling in mouse dentate gyrus. Journal of Neurophysiology. 88: ... 2007) Somatostatin in the dentate gyrus. Progress in Brain Research. 163: 265-84. ...
The avoidance behaviour to somatostatin in Sstr2 transgenic pets could be inhibited using the somatostatin antagonist ... Somatostatin receptors bind two isoforms of the tetradecapeptide, SST-14 and -28 [9,10]. Both possess broad regulatory features ... In structure-function research using a -panel of somatostatin-14 analogues, we recognized key residues mixed up in conversation ... of somatostatin-14 with Sstr2. Summary Our outcomes illustrate an extraordinary evolutionary plasticity in relationships ...
Somatostatin analogs competitively bind to the same somatostatin receptors as lutetium Lu 177-dota-tate and may affect its ... Somatostatin analogs competitively bind to the same somatostatin receptors as lutetium Lu 177-dota-tate and may affect its ... Somatostatin analogs competitively bind to the same somatostatin receptors as CU 64 dotatate and may affect imaging. Image ... Somatostatin analogs competitively bind to the same somatostatin receptors as Ga 68 dotatate and may affect imaging. Image ...
Somatostatin immunoreactivity in esophageal premotor neurons of the rat. Neurosci Lett 1998;250:201-204. , Article , ChemPort , ... Wang YT, Neuman RS, Bieger D. Somatostatin inhibits nicotinic cholinoceptor mediated excitation in rat ambigual motoneurons in ... Wang YT, Zhang M, Neuman RS, Bieger D. Somatostatin regulates excitatory amino acid receptor-mediated fast excitatory ... anatomical evidence for somatostatin-28-immunoreactive interneurons subserving reflex control of oesophageal motility. J ...
Clinical features of carcinoid syndrome and the use of somatostatin analogue in its management. / Vinik, A. I.; Thompson, N.; ... Vinik, AI, Thompson, N, Eckhauser, F & Moattari, AR 1989, Clinical features of carcinoid syndrome and the use of somatostatin ... Clinical features of carcinoid syndrome and the use of somatostatin analogue in its management. In: Acta Oncologica. 1989 ; Vol ... Clinical features of carcinoid syndrome and the use of somatostatin analogue in its management. Acta Oncologica. 1989;28(3):389 ...
Pegvisomant (PEGV) is widely used, alone or with somatostatin analogs (SSA), for GH-secreting pituitary tumors poorly ... Long-term treatment of somatostatin analog-refractory growth hormone-secreting pituitary tumors with pegvisomant alone or ... Long-term treatment of somatostatin analog-refractory growth hormone-secreting pituitary tumors with pegvisomant alone or ... combined with long-acting somatostatin analogs: a retrospective analysis of…. Overview of attention for article published in ...
J:27406 ODowd BF, et al., The cloning and chromosomal mapping of two novel human opioid-somatostatin-like receptor genes, GPR7 ...
Effect of somatostatin.. Systemic insulin concentrations were unchanged during somatostatin administration (Fig. 3). Ghrelin ... Reubi JC: Somatostatin receptors in the gastrointestinal tract in health and disease. Yale J Biol Med ... Zaki M, Harrington L, McCuen R, Coy DH, Arimura A, Schubert ML: Somatostatin receptor subtype 2 mediates inhibition of gastrin ... placebo). GH and IGF-1 concentrations decreased by coinfusion of somatostatin with glucose (P , 0.05) (Table 1). ...
Somatostatin 14, human, rat, mouse, pig, chicken, frog *AGCKNFFWKTFTSC (Disulfide bridge: 3-14) ...
Immunocytochemical demonstration of LH-RH, somatostatin, and ACTH-like peptide in osmium-postfixed, resin-embedded median ...
In addition, a particular class of neurons, somatostatin-positive neurons, is required to translate that memory into fear ... Particularly important in this process, the team discovered, were somatostatin-positive (SOM+) neurons. Somatostatin is a ... In addition, a particular class of neurons, somatostatin-positive neurons, is required to translate that memory into fear ... January 28, 2013. Source:. Cold Spring Harbor Laboratory. Summary:. Neuroscientists have shed new light on the brain circuit ...
Acts primarily on somatostatin receptor subtypes II and V. Inhibits growth hormone (GH) secretion and has a multitude of other ...
  • The somatostatin receptors are G protein-coupled receptors. (wikipedia.org)
  • As a radiopharmaceutical compound that is selective for somatostatin receptors, there is research being done to for these radiolabeled compounds to act as diagnostic tests in PET scans for neuroendocrine tumors and other tumors not previously targeted with radiolabeled somatostatin receptor agonists, and to act as radiopharmaceutical therapeutic compound, more specifically to conduct peptide radionuclide receptor therapy. (wikipedia.org)
  • However, these somatostatin receptor antagonists showed a higher tumor uptake despite its lower affinity for ssrt receptors, due to being able to bind a receptor despite its activation status. (wikipedia.org)
  • The advent of radiolabeled somatostatin analogs in the targeted imaging and radionuclide therapy of tumors overexpressing somatostatin receptors has paved the way for other radiopeptides to target alternative cancer-associated peptide receptor systems ( 1 - 4 ). (snmjournals.org)
  • Somatostatin receptors bind two isoforms of the tetradecapeptide, SST-14 and -28 [9,10]. (exposed-skin-care.net)
  • Immunocytochemical detection of somatostatin receptors sst1, sst2A, sst2B, and sst3 in paraffin-embedded breast cancer tissue using subtype-specific antibodies. (consensus.app)
  • Because the antiproliferative action of octreotide depends on at least the presence of somatostatin receptors, it is crucial to determine the pattern of somatostatin receptor protein expression on the tumor cells. (consensus.app)
  • Somatostatin is best known as a regulator of growth hormone secretion, though somatostatin receptors are found in the lung and expression of these receptors is increased in IPF. (bmj.com)
  • Characterization of cloned somatostatin receptors SSTR4 and SSTR5. (uchicago.edu)
  • Cloned somatostatin receptors: identification of subtype-selective peptides and demonstration of high affinity binding of linear peptides. (uchicago.edu)
  • Pharmacological properties of two cloned somatostatin receptors. (uchicago.edu)
  • Somatostatin receptor (SSTR) expression constitutes a pivotal cornerstone for accurate radiological detection and medical treatment of small intestinal neuroendocrine tumors (SI-NETs), and the development of somatostatin analogues for these purposes have revolutionized the clinical work-up. (nel.edu)
  • In structure-function research using a -panel of somatostatin-14 analogues, we recognized key residues mixed up in conversation of somatostatin-14 with Sstr2. (exposed-skin-care.net)
  • Somatostatin analogues are manufactured versions and have become the cornerstone therapy for many functional NETs (and also for Acromegaly). (ronnyallan.net)
  • Expressed in terms of exogenous doses, SS-14 (ID50: 1.49 nmol · kg-1 · h-1) was 3.4 times more potent than SS-28 (ID50: 5.12 nmol · kg-1 · h-1) as an inhibitor of gastric acid secretion. (uaeu.ac.ae)
  • Somatostatinomas are rare neuroendocrine tumors that arise from the pancreas or the gastrointestinal tract and are characterized by excessive secretion of somatostatin hormone by tumor cells of D-cell origin. (medscape.com)
  • Acts primarily on somatostatin receptor subtypes II and V. Inhibits growth hormone (GH) secretion and has a multitude of other endocrine and nonendocrine effects, including inhibition of glucagon, VIP, and GI peptides. (medscape.com)
  • Acts as the functionally dominant somatostatin receptor in pancreatic alpha- and beta-cells where it mediates the inhibitory effect of somatostatin-14 on hormone secretion. (cusabio.com)
  • Secretion from many neuroendocrine and endocrine tumours is inhibited by natural somatostatin. (ronnyallan.net)
  • Pegvisomant (PEGV) is widely used, alone or with somatostatin analogs (SSA), for GH-secreting pituitary tumors poorly controlled by SSAs alone. (altmetric.com)
  • Impact of carcinoid syndrome symptoms and long-term use of somatostatin analogs on quality of life in patients with carcinoid syndrome: A survey study. (harvard.edu)
  • Regional differences in somatostatin receptor 2 (SSTR2) immunoreactivity is coupled to level of bowel invasion in small intestinal neuroendocrine tumors. (nel.edu)
  • Inhibition of cell proliferation by the somatostatin analogue RC-160 is mediated by somatostatin receptor subtypes SSTR2 and SSTR5 through different mechanisms. (uchicago.edu)
  • Immunological detection of isoforms of the somatostatin receptor subtype, SSTR2. (uchicago.edu)
  • Gi alpha 3 and G(o) alpha selectively associate with the cloned somatostatin receptor subtype SSTR2. (uchicago.edu)
  • Diarrhea and steatorrhea are common symptoms of pancreatic somatostatin tumors and contribute to weight loss. (medscape.com)
  • The expression of somatostatin receptor 2 was was negatively correlated with malignancy: normal tissues and some of the benign tumors had the highest levels. (cusabio.com)
  • In the vast majority of positively stained tumors, somatostatin receptor-Li was uniformly present on nearly all tumor cells. (consensus.app)
  • The radiolabeled somatostatin receptor antagonists share the following structure: The antagonist has a peptide moiety. (wikipedia.org)
  • Somatostatin acetate is commonly used in the clinical treatment of severe acute esophageal varicose hemorrhage, severe acute gastric and duodenal ulcer hemorrhage, acute erosive gastritis or hemorrhagic gastritis, pancreatic, bile and intestinal recurrent adjuvant therapy, and diabetic ketoacidosis. (industrialchemgroup.com)
  • Recurrent Glioblastoma Multiforme (grade IV - WHO 2007): a case of complete objective response - concomitant administration of Somatostatin / Octreotide, Retinoids, Vit E, Vit D3, Vit C, Melatonin, D2 R agonists (Di Bella Method. (nel.edu)
  • Immunocytochemical detection of somatostatin receptor subtypes in breast cancer tissue may provide more precise information for predicting response to octreotide therapy than reverse transcription-PCR. (consensus.app)
  • The long-acting somatostatin analogue octreotide (SMS 201-995) inhibits growth of certain breast cancer cell lines in vivo and in vitro. (consensus.app)
  • These CeA GABA neurons express dynorphin, somatostatin and/or corticotropin releasing hormone. (iasp-pain.org)
  • We describe a novel pathway, consisting of inhibition by dynorphin, somatostatin and corticotropin-releasing hormone expressing neurons in the central nucleus of the amygdala that project to the parabrachial nucleus (PB). (iasp-pain.org)
  • In addition, a particular class of neurons, somatostatin-positive neurons, is required to translate that memory into fear responses. (sciencedaily.com)
  • Particularly important in this process, the team discovered, were somatostatin-positive (SOM+) neurons. (sciencedaily.com)
  • There are also some non-radiopharmaceutical compounds that are developed as competitive inhibitors of somatostatin, such as the hormone antagonist cyclosomatostatin. (wikipedia.org)
  • The 28-amino acid peptide ghrelin has been identified as the endogenous ligand of the pituitary growth hormone (GH) secretagogue receptor ( 1 ). (diabetesjournals.org)
  • Somatostatin is a hormone that affects neurotransmitter release. (sciencedaily.com)
  • A full description of somatostatinoma syndrome followed in 1979 when Krejs and colleagues described the morphologic and biochemical properties of a tumor of the ampulla of Vater in a 52-year-old man with distinct clinical symptoms and excessive somatostatin levels. (medscape.com)
  • Of particular clinical relevance is the independence of CCK-2/gastrin-R status on the degree of tumor differentiation in human MTCs ( 5 , 6 ), whereas, in advanced and clinically aggressive forms of the disease, somatostatin receptor expression is lacking ( 7 , 8 ). (snmjournals.org)
  • Clinical significance of the UGT1A1*28 allele detection in HIV-infected patients. (cdc.gov)
  • The plasma immunoreactive half-life of SS-28 (6.1 min) was double that for SS-14 (2.4 min) possibly due to a slower theoretical metabolic clearance rate of the larger peptide (30 and 87 ml · kg -1 · min -1 , respectively). (uaeu.ac.ae)
  • Somatostatin is a cyclic peptide present in both 14-amino acid and 28-amino acid forms. (medscape.com)
  • Enhancers containing the CGTCA motif from the somatostatin and adenovirus genes compete for binding of nuclear proteins from C6 glioma and PC12 cells to the vasoactive intestinal peptide enhancer, suggesting that CGTCA-containing enhancers interact with similar transacting factors. (elsevierpure.com)
  • Somatostatin receptor antagonists (or somatostatin inhibitors) are a class of chemical compounds that work by imitating the structure of the neuropeptide somatostatin. (wikipedia.org)
  • The gastric exocrine inhibitory activities of somatostatin-28 (SS-28) and somatostatin-14 (SS-14) were determined in conscious cats prepared with gastric fistulae. (uaeu.ac.ae)
  • Somatostatin receptor antagonists are divided by generation based on the type of the subtype receptor antagonist. (wikipedia.org)
  • 2008 ) Somatostatin receptor subtype 4 couples to the M-current to regulate seizures. (neurotree.org)
  • Gi alpha 1 selectively couples somatostatin receptor subtype 3 to adenylyl cyclase: identification of the functional domains of this alpha subunit necessary for mediating the inhibition by somatostatin of cAMP formation. (uchicago.edu)
  • Mutation of an aspartate at residue 89 in somatostatin receptor subtype 2 prevents Na+ regulation of agonist binding but does not alter receptor-G protein association. (uchicago.edu)
  • Ghrelin plasma concentration was studied during concomitant exogenous hyperinsulinemia, inhibition of endogenous insulin production by somatostatin infusion, and placebo time control, respectively. (diabetesjournals.org)
  • Activation of human somatostatin receptor type 2 causes inhibition of cell growth in transfected HEK293 but not in transfected CHO cells. (uchicago.edu)
  • In one of the resulting transgenic lines, called GIN ( G FP-expressing I nhibitory N eurons), EGFP was found to be expressed in a subpopulation of somatostatin-containing GABAergic interneurons in the hippocampus and neocortex. (jneurosci.org)
  • Somatostatin receptor-like immunoreactivity (Li) was predominantly localized to the plasma membrane of the tumor cells. (consensus.app)
  • Figure 3 Immunohistochemical detection of somatostatin (sst) receptor sst2A in naïve mouse lung and after bleomycin instillation. (bmj.com)
  • In the present study, we have raised polyclonal antibodies to somatostatin receptor subtypes (ssts) sst1, sst2A, sst2B, and sst3 using peptides corresponding to their COOH-terminal sequences. (consensus.app)
  • Tallent MK, Qiu C. ( 2008 ) Somatostatin: an endogenous antiepileptic. (neurotree.org)
  • The reduced activity of SS-28, compared with SS-14, against gastric exocrine secretions contrasts with its more potent effects in the pituitary and pancreas. (uaeu.ac.ae)
  • POPULATION: Sixty-three patients with T2DM (ages: 22-69 years, 17 females) confirmed by renal biopsy divided into two subgroups (28 DN and 35 NDRD). (bvsalud.org)
  • Variants in motilin, somatostatin and their receptor genes and risk of biliary tract cancers and stones in Shanghai, China. (cdc.gov)
  • As pituitary gland and pituitary adenomas are known to express SSTRs, somatostatin receptor scintigraphy can be used for imaging. (unboundmedicine.com)
  • We have reviewed the literature on current therapy of carcinoid patients with special emphasis on the use of the somatostatin analogue SMS 20-1995. (johnshopkins.edu)
  • when used, it reduces the frequency of short-acting somatostatin analog rescue therapy. (guidelinecentral.com)
  • Somatostatin receptor-based PET/CT imaging using 68Ga-DOTANOC has become a popular noninvasive imaging modality for evaluation of patients with NETs. (unboundmedicine.com)
  • L'étude portait sur 20 patients atteints d'un carcinome gastrique, 20 patients souffrant d'une gastrite à H. pylori et 20 personnes en tant que groupe témoin. (who.int)
  • 2002 ) Somatostatin depresses long-term potentiation and Ca2+ signaling in mouse dentate gyrus. (neurotree.org)
  • The structure of somatostatin receptor antagonists are similar to that of the agonists. (wikipedia.org)
  • Both peptides had similar apparent distribution volumes (SS-14, 306 and SS-28, 263 ml · kg -1 ). (uaeu.ac.ae)
  • Borie and colleagues describe an animal experiment using the bleomycin model with a new somatostatin analogue (SOM230). (bmj.com)